Reported by DallasNews 3 hours ago.
Warhol's glam portrait of Queen Elizabeth is just one reason to see these royal portraits in Texas
↧
↧
W.H.P.M., Inc. Files Patent Infringement Lawsuit Against Healgen Scientific LLC
The lawsuit seeks compensatory damages in addition to a permanent injunction on Healgen’s manufacture, sale or import of products alleged to be infringing on W.H.P.M.’s patent.
IRWINDALE, Calif. (PRWEB) November 12, 2018
W.H.P.M., Inc. (“W.H.P.M.”), a leading developer and manufacturer of rapid drugs of abuse and medical diagnostic devices, announced today that it has filed a lawsuit for patent infringement against Healgen Scientific Limited Liability Company, a Texas company (“Healgen”).
The lawsuit, filed in the United States District Court for the Southern District of Texas, Houston Division (Case number: 4:2018cv02302) alleges infringement of United States Patent No. 7,927,562 (“'562 Patent”), titled “Collection and Assay Device for Biological Fluid.”
W.H.P.M. alleges that Healgen has been and is now infringing the '562 Patent by making, using, selling and/or offering for sale in the United States, and/or importing into the United States, products falling within the scope of one or more claims of the '562 Patent, including but not limited to Healgen’s Saliva Screen Test and/or Healgen’s One Step Oral Fluid Drug Test (“Accused Healgen Products”). WHPM further alleges that Healgen knowingly and intentionally causes its customers to directly infringe the '562 Patent through various means, including but not limited to, the marketing, selling and offering for sale the Accused Healgen Products to its customers.
WHPM seeks monetary damages and injunctive relief enjoining Healgen and any others in any way associated with them from making, using, selling and/or offering for sale in the United States, and/or importing into the United States, products falling within the scope of one or more claims of the '562 Patent, including but not limited to Healgen’s Saliva Screen Test and/or Healgen’s One Step Oral Fluid Drug Test or in any other manner infringing, inducing others to infringe or contributing to the infringement of the '562 Patent.
“We have invested significant time and resources into developing our oral fluid drug tests and collection systems,” says Dr. John Wan, founder and President of W.H.P.M., Inc. “Our intellectual property and our investments in R&D must be protected. As a result of activities we allege infringe on W.H.P.M.’s patent, we are taking legal action.”
W.H.P.M intends to vigorously defend its intellectual property and is prepared to pursue additional action against those infringing on its intellectual property.
About W.H.P.M., Inc.
W.H.P.M., Inc., established in 1993, is headquartered in Irwindale, Calif. W.H.P.M. is a global leader in the research, development, and deployment of the most advanced and innovative one-step membrane tests and medical diagnostics devices on the market today. W.H.P.M. offers customers a variety of fast-turnaround services for rapid diagnostics, including OEM production, customized assembly, and private labeling. It assists companies in rapidly producing a wide array of products by utilizing its extensive experience in advanced bio-technology and design/manufacturing systems. Learn more at whpm.com. Reported by PRWeb 2 hours ago.
IRWINDALE, Calif. (PRWEB) November 12, 2018
W.H.P.M., Inc. (“W.H.P.M.”), a leading developer and manufacturer of rapid drugs of abuse and medical diagnostic devices, announced today that it has filed a lawsuit for patent infringement against Healgen Scientific Limited Liability Company, a Texas company (“Healgen”).
The lawsuit, filed in the United States District Court for the Southern District of Texas, Houston Division (Case number: 4:2018cv02302) alleges infringement of United States Patent No. 7,927,562 (“'562 Patent”), titled “Collection and Assay Device for Biological Fluid.”
W.H.P.M. alleges that Healgen has been and is now infringing the '562 Patent by making, using, selling and/or offering for sale in the United States, and/or importing into the United States, products falling within the scope of one or more claims of the '562 Patent, including but not limited to Healgen’s Saliva Screen Test and/or Healgen’s One Step Oral Fluid Drug Test (“Accused Healgen Products”). WHPM further alleges that Healgen knowingly and intentionally causes its customers to directly infringe the '562 Patent through various means, including but not limited to, the marketing, selling and offering for sale the Accused Healgen Products to its customers.
WHPM seeks monetary damages and injunctive relief enjoining Healgen and any others in any way associated with them from making, using, selling and/or offering for sale in the United States, and/or importing into the United States, products falling within the scope of one or more claims of the '562 Patent, including but not limited to Healgen’s Saliva Screen Test and/or Healgen’s One Step Oral Fluid Drug Test or in any other manner infringing, inducing others to infringe or contributing to the infringement of the '562 Patent.
“We have invested significant time and resources into developing our oral fluid drug tests and collection systems,” says Dr. John Wan, founder and President of W.H.P.M., Inc. “Our intellectual property and our investments in R&D must be protected. As a result of activities we allege infringe on W.H.P.M.’s patent, we are taking legal action.”
W.H.P.M intends to vigorously defend its intellectual property and is prepared to pursue additional action against those infringing on its intellectual property.
About W.H.P.M., Inc.
W.H.P.M., Inc., established in 1993, is headquartered in Irwindale, Calif. W.H.P.M. is a global leader in the research, development, and deployment of the most advanced and innovative one-step membrane tests and medical diagnostics devices on the market today. W.H.P.M. offers customers a variety of fast-turnaround services for rapid diagnostics, including OEM production, customized assembly, and private labeling. It assists companies in rapidly producing a wide array of products by utilizing its extensive experience in advanced bio-technology and design/manufacturing systems. Learn more at whpm.com. Reported by PRWeb 2 hours ago.
↧
Cruz: "Reason to be concerned" in Florida recount
Sen. Ted Cruz, R-Texas, discusses the vote recounts in Florida's statewide elections and President Trump's order restricting asylum-seekers at the border with Margaret Brennan.
Reported by CBS News 1 hour ago.
↧
MOLOGEN AG: Lefitolimod - First clinical data in combination with a checkpoint inhibitor and further preclinical results presented at SITC 2018
DGAP-News: MOLOGEN AG / Key word(s): Conference
12.11.2018 / 10:50
The issuer is solely responsible for the content of this announcement.
--------------------
PRESS RELEASE N 26/2018 of 12 November 2018
*MOLOGEN AG: Lefitolimod - First clinical data in combination with a checkpoint inhibitor and further preclinical results presented at SITC 2018 *
Berlin, 12 November 2018 - *The biopharmaceutical company MOLOGEN AG presented two posters on its lead compound, the TLR9 agonist lefitolimod at the SITC 2018 Congress (The Society for Immunotherapy of Cancer) in Washington D.C., U.S. (07 - 11 November 2018). The first poster from the MD Anderson Cancer Center in collaboration with MOLOGEN is featuring results from the ongoing clinical combination study of lefitolimod with the checkpoint inhibitor ipilimumab (Yervoy^(R)). The data confirm the favorable safety profile of lefitolimod, also in combination with ipilimumab. Importantly, the detected increase of cytotoxic T cells in tumor biopsies supports the mode-of-action of lefitolimod regarding the beneficial modulation of the tumor microenvironment (TME) already established in pre-clinical models now also in humans. The second poster presents data on lefitolimod-mediated changes of the TME and the induction of a sustained anti-tumor immune memory. Monotherapy with lefitolimod resulted in a clear beneficial modulation of the TME together with a reduced tumor growth in a murine colorectal cancer model. Pronounced effects were also observed in a breast cancer model with a complete tumor regression in the majority of mice. In a subsequent re-challenge study all surviving mice rejected not only the initially used but also a different tumor cell line, indicating the induction of a broad systemic immune response against various tumor types. In summary the presented data impressively support the assumption that lefitolimod beneficially modulates the TME and may hence be an ideal partner for immuno-oncology combination approaches, i.e. with checkpoint inhibitors. *
"We are excited about the first clinical data on lefitolimod in combination with a checkpoint inhibitor. Importantly, besides confirming the favorable safety profile, we see clear hints for beneficial TME-modulating effects in patients. These clinical results are nicely complemented with further pre-clinical data impressively supporting the potential of lefitolimod in immuno-oncology. We all know that checkpoint inhibitors need help to fully unfold their enormous potential and we have now even more reasons to believe that our TLR9 agonist lefitolimod will play a major role also in this context", said Dr Matthias Baumann, CMO of MOLOGEN AG.
*First data of combination study (lefitolimod and ipilimumab) confirm safety and mode-of-action of the TLR9 agonist*
The aim of the study titled "A Phase I Trial of Ipilimumab (Immunotherapy) and lefitolimod (TLR Agonist) in Patients with Advanced Solid Malignancies" is to initially find the highest tolerable dose of lefitolimod that can be given in combination with the commercially available immunotherapeutic agent Yervoy^(R) (ipilimumab) to patients with solid tumors. The safety as well as pharmacodynamic effects of this drug combination are also being studied. The data presented at the SITC Conference by the team of the MD Anderson Cancer Center, Houston, Texas, who is conducting the clinical study, confirm lefitolimod's mode-of-action with respect to an increased proportion and activation of cytotoxic T cells in tumor biopsies. Furthermore, PD-1 expression increased after treatment suggesting potential benefit from additional PD-1 blockade. The combination of MOLOGEN's TLR9 agonist with the checkpoint inhibitor presented with a favourable safety profile and no dose-limiting toxicities (DLTs) have been encountered up to the highest dose level.
The clinical combination study is conducted by MD Anderson Cancer Center. MOLOGEN provides the TLR9 agonist lefitolimod and funds the study. This is the first time that lefitolimod is being clinically evaluated in combination with a checkpoint inhibitor. If lefitolimod enhances the efficacy of immune checkpoint blockade, this could expand the potential range of applications of the compound.
*Impressive immuno-oncological effects of lefitolimod in preclinical models*
After intratumoral injection of lefitolimod an increased infiltration of T cells (CD3+ T cells, especially CD8+ T cells) as well as of anti-tumoral M1 macrophages into the tumor was observed. Importantly, this beneficial TME modulation from an immunosuppressed ("cold") towards a more immunoreactive ("hot") stage translated into a reduction of tumor growth in the mice. Beyond that the tumors of the majority of mice in another model completely disappeared. Notably, all surviving mice presented with a sustained anti-tumor immune memory not only against the same cancer cells, but also against various types of other tumors. This indicates the lefitolimod-induced generation of a systemic immune memory against shared tumor antigens expressed across different tumor cell lines.
For more information on SITC 2018 please visit the website: https://www.sitcancer.org/2018/home
*MOLOGEN AG*
MOLOGEN AG is a biopharmaceutical Company and a pioneer in the field of immunotherapy on account of its unique active agents and technologies. Alongside a focus on immuno-oncology, MOLOGEN develops immunotherapies for the treatment of infectious diseases.
The focus of the development work is on the product family of DNA-based TLR9 agonists. This includes the lead compound lefitolimod and the next-generation molecule family EnanDIM^(R).
The immunotherapeutic agent lefitolimod is the Company's lead compound and is currently being investigated in a pivotal trial. It is regarded as the best-in-class TLR9 agonist. Treatment with lefitolimod triggers a broad and strong activation of the immune system. On account of this mode of action, lefitolimod could potentially be used in various indications. Lefitolimod is currently being developed within the framework of a pivotal study for first line maintenance therapy for colorectal cancer. Key data of the phase II IMPULSE study in extensive-stage small cell lung cancer (ES-SCLC) and the data from the extension phase of the TEACH study in HIV have been published. In addition, lefitolimod is currently being investigated in a phase I combination study with the checkpoint inhibitor ipilimumab (Yervoy^(R)) in various cancer indications. Along with various checkpoint inhibitors, lefitolimod, which is being investigated as part of a phase III clinical trial currently, is one of the few near-to-market product candidates in the field of immuno-oncology.
MOLOGEN's pipeline focus is on new innovative immunotherapies to treat diseases for which there is a great medical demand in particular.
MOLOGEN AG is a publicly listed Company, headquartered in Berlin. The shares (ISIN, DE000A2LQ900/SIN: A2L Q90) are listed in the Prime Standard of the German Stock Exchange.
www.mologen.com* *
*Contact*
*Claudia Nickolaus*
Head of Investor Relations & Corporate Communications
Tel: +49 - 30 - 84 17 88 - 38
Fax: +49 - 30 - 84 17 88 - 50
investor@MOLOGEN.com
*Note about risk for future predictions*
Certain information in this report contains forward-looking statements or the corresponding statements with negation or versions deviating from this or comparable terminology. These are described as forward-looking statements. In addition, all of the information given here that refers to planned or future results of business areas, key financial figures, developments of the financial situation or other financial figures or statistical data, is to be understood as such forward-looking statements. The company points out to investors that they should not rely on these forward-looking statements as predictions about actual future events. The company is not obligated and refuses to accept any liability for the forward-looking statements and has no obligation to update such statements in order to accurately reflect the current situation.
--------------------
12.11.2018 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de --------------------
Language: English
Company: MOLOGEN AG
Fabeckstraße 30
14195 Berlin
Germany
Phone: 030 / 841788-0
Fax: 030 / 841788-50
E-mail: presse@mologen.com
Internet: www.mologen.com
ISIN: DE000A2LQ900
WKN: A2LQ90
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
End of News DGAP News Service Reported by EQS Group 1 hour ago.
12.11.2018 / 10:50
The issuer is solely responsible for the content of this announcement.
--------------------
PRESS RELEASE N 26/2018 of 12 November 2018
*MOLOGEN AG: Lefitolimod - First clinical data in combination with a checkpoint inhibitor and further preclinical results presented at SITC 2018 *
Berlin, 12 November 2018 - *The biopharmaceutical company MOLOGEN AG presented two posters on its lead compound, the TLR9 agonist lefitolimod at the SITC 2018 Congress (The Society for Immunotherapy of Cancer) in Washington D.C., U.S. (07 - 11 November 2018). The first poster from the MD Anderson Cancer Center in collaboration with MOLOGEN is featuring results from the ongoing clinical combination study of lefitolimod with the checkpoint inhibitor ipilimumab (Yervoy^(R)). The data confirm the favorable safety profile of lefitolimod, also in combination with ipilimumab. Importantly, the detected increase of cytotoxic T cells in tumor biopsies supports the mode-of-action of lefitolimod regarding the beneficial modulation of the tumor microenvironment (TME) already established in pre-clinical models now also in humans. The second poster presents data on lefitolimod-mediated changes of the TME and the induction of a sustained anti-tumor immune memory. Monotherapy with lefitolimod resulted in a clear beneficial modulation of the TME together with a reduced tumor growth in a murine colorectal cancer model. Pronounced effects were also observed in a breast cancer model with a complete tumor regression in the majority of mice. In a subsequent re-challenge study all surviving mice rejected not only the initially used but also a different tumor cell line, indicating the induction of a broad systemic immune response against various tumor types. In summary the presented data impressively support the assumption that lefitolimod beneficially modulates the TME and may hence be an ideal partner for immuno-oncology combination approaches, i.e. with checkpoint inhibitors. *
"We are excited about the first clinical data on lefitolimod in combination with a checkpoint inhibitor. Importantly, besides confirming the favorable safety profile, we see clear hints for beneficial TME-modulating effects in patients. These clinical results are nicely complemented with further pre-clinical data impressively supporting the potential of lefitolimod in immuno-oncology. We all know that checkpoint inhibitors need help to fully unfold their enormous potential and we have now even more reasons to believe that our TLR9 agonist lefitolimod will play a major role also in this context", said Dr Matthias Baumann, CMO of MOLOGEN AG.
*First data of combination study (lefitolimod and ipilimumab) confirm safety and mode-of-action of the TLR9 agonist*
The aim of the study titled "A Phase I Trial of Ipilimumab (Immunotherapy) and lefitolimod (TLR Agonist) in Patients with Advanced Solid Malignancies" is to initially find the highest tolerable dose of lefitolimod that can be given in combination with the commercially available immunotherapeutic agent Yervoy^(R) (ipilimumab) to patients with solid tumors. The safety as well as pharmacodynamic effects of this drug combination are also being studied. The data presented at the SITC Conference by the team of the MD Anderson Cancer Center, Houston, Texas, who is conducting the clinical study, confirm lefitolimod's mode-of-action with respect to an increased proportion and activation of cytotoxic T cells in tumor biopsies. Furthermore, PD-1 expression increased after treatment suggesting potential benefit from additional PD-1 blockade. The combination of MOLOGEN's TLR9 agonist with the checkpoint inhibitor presented with a favourable safety profile and no dose-limiting toxicities (DLTs) have been encountered up to the highest dose level.
The clinical combination study is conducted by MD Anderson Cancer Center. MOLOGEN provides the TLR9 agonist lefitolimod and funds the study. This is the first time that lefitolimod is being clinically evaluated in combination with a checkpoint inhibitor. If lefitolimod enhances the efficacy of immune checkpoint blockade, this could expand the potential range of applications of the compound.
*Impressive immuno-oncological effects of lefitolimod in preclinical models*
After intratumoral injection of lefitolimod an increased infiltration of T cells (CD3+ T cells, especially CD8+ T cells) as well as of anti-tumoral M1 macrophages into the tumor was observed. Importantly, this beneficial TME modulation from an immunosuppressed ("cold") towards a more immunoreactive ("hot") stage translated into a reduction of tumor growth in the mice. Beyond that the tumors of the majority of mice in another model completely disappeared. Notably, all surviving mice presented with a sustained anti-tumor immune memory not only against the same cancer cells, but also against various types of other tumors. This indicates the lefitolimod-induced generation of a systemic immune memory against shared tumor antigens expressed across different tumor cell lines.
For more information on SITC 2018 please visit the website: https://www.sitcancer.org/2018/home
*MOLOGEN AG*
MOLOGEN AG is a biopharmaceutical Company and a pioneer in the field of immunotherapy on account of its unique active agents and technologies. Alongside a focus on immuno-oncology, MOLOGEN develops immunotherapies for the treatment of infectious diseases.
The focus of the development work is on the product family of DNA-based TLR9 agonists. This includes the lead compound lefitolimod and the next-generation molecule family EnanDIM^(R).
The immunotherapeutic agent lefitolimod is the Company's lead compound and is currently being investigated in a pivotal trial. It is regarded as the best-in-class TLR9 agonist. Treatment with lefitolimod triggers a broad and strong activation of the immune system. On account of this mode of action, lefitolimod could potentially be used in various indications. Lefitolimod is currently being developed within the framework of a pivotal study for first line maintenance therapy for colorectal cancer. Key data of the phase II IMPULSE study in extensive-stage small cell lung cancer (ES-SCLC) and the data from the extension phase of the TEACH study in HIV have been published. In addition, lefitolimod is currently being investigated in a phase I combination study with the checkpoint inhibitor ipilimumab (Yervoy^(R)) in various cancer indications. Along with various checkpoint inhibitors, lefitolimod, which is being investigated as part of a phase III clinical trial currently, is one of the few near-to-market product candidates in the field of immuno-oncology.
MOLOGEN's pipeline focus is on new innovative immunotherapies to treat diseases for which there is a great medical demand in particular.
MOLOGEN AG is a publicly listed Company, headquartered in Berlin. The shares (ISIN, DE000A2LQ900/SIN: A2L Q90) are listed in the Prime Standard of the German Stock Exchange.
www.mologen.com* *
*Contact*
*Claudia Nickolaus*
Head of Investor Relations & Corporate Communications
Tel: +49 - 30 - 84 17 88 - 38
Fax: +49 - 30 - 84 17 88 - 50
investor@MOLOGEN.com
*Note about risk for future predictions*
Certain information in this report contains forward-looking statements or the corresponding statements with negation or versions deviating from this or comparable terminology. These are described as forward-looking statements. In addition, all of the information given here that refers to planned or future results of business areas, key financial figures, developments of the financial situation or other financial figures or statistical data, is to be understood as such forward-looking statements. The company points out to investors that they should not rely on these forward-looking statements as predictions about actual future events. The company is not obligated and refuses to accept any liability for the forward-looking statements and has no obligation to update such statements in order to accurately reflect the current situation.
--------------------
12.11.2018 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de --------------------
Language: English
Company: MOLOGEN AG
Fabeckstraße 30
14195 Berlin
Germany
Phone: 030 / 841788-0
Fax: 030 / 841788-50
E-mail: presse@mologen.com
Internet: www.mologen.com
ISIN: DE000A2LQ900
WKN: A2LQ90
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
End of News DGAP News Service Reported by EQS Group 1 hour ago.
↧
Varner's 21 points help UTRGV beat TAMU-CC 76-69
Lesley Varner II scored nine of his 21 points in the final 2:09 to help UT-Rio Grande Valley beat Texas A&M-Corpus Christi 76-69
Reported by FOX Sports 6 hours ago.
↧
↧
Mond’s play big talking point for fans
Texas A&M’s Kellen Mond doesn’t have much of a chance of becoming the program’s greatest quarterback, but he’s rapidly becoming the most debated.
Reported by Harrison Daily 3 hours ago.
↧
Voltabox Doubles Revenue in First Nine Months of the Year With Increasing Profitability - Forecast for the Year as a Whole Confirmed
DGAP-News: Voltabox AG / Key word(s): Interim Report
13.11.2018 / 07:30
The issuer is solely responsible for the content of this announcement.
--------------------
*Voltabox Doubles Revenue in First Nine Months of the Year With Increasing Profitability - Forecast for the Year as a Whole Confirmed*
*- Group sales double to EUR 33.5 million*
*- Increasing market penetration in intralogistics results in high level of utilization*
*- EBITDA grows from EUR -0.3 million in the prior year to EUR 4.9 million*
*- EBIT increases to EUR 2.3 million; EBIT margin improves considerably to 7.0 percent*
*- Number of employees doubles to 193 in the first nine months of the year*
*- Forecast for 2018 confirmed: revenue of EUR 65-70 million with an EBIT margin of about 7 percent*
*Delbrück, Germany, November 13, 2018 *- Voltabox AG [ISIN DE000A2E4LE9] published its results for the first nine months of 2018 today and confirmed its forecast for the year as a whole.
"*Our focus on lucrative e-mobility niche markets is beginning to pay off," says Jürgen Pampel, Chief Executive Officer of Voltabox AG. "Especially in the area of intralogistics, there is a very strong level of demand for our technology. We had an accordingly high level of utilization in the highly automated field of modules production in the third quarter. A significant part of this increased demand is attributable to our cooperation with our partner Triathlon, which we relaunched in the second quarter. We are also benefiting from our direct market access in the area of intralogistics."*
Thanks to the further rise in demand, Voltabox achieved revenue of EUR 15.4 million in the third quarter. The increase in the inventory of finished goods and work in progress should also be included in an assessment of the company's total operating performance. The former amounts to EUR 7.2 million and is mainly attributable to inventory build-up of modules produced for use in forklifts and other intralogistics applications. In the period from January to September, Voltabox generated revenue of EUR 33.5 million and thus grew by 105 percent over the prior year (EUR 16.3 million). The EBIT margin also increased very strongly year-over-year and amounted to 7.0 percent for the first nine months of the year (prior year: -10.7 percent).
*Modules for Intralogistics and Battery Systems for Trolleybuses Shape Revenue Growth*
In addition to large quantities of battery modules for intralogistics, Voltabox produced battery systems for use in trolleybuses in the third quarter. These are intended for the local public transport grids of Seattle, San Francisco and Lucerne. Voltabox also serially produced and delivered the first battery systems for Schäffer, a compact-, wheel- and teleloader provider, in the third quarter. It's the company's intention to at least maintain the same level of production output in the fourth quarter. At the same time, series production of starter batteries for BMW Motorrad is now finally set to begin. This should be reflected in additional revenue at the start of the coming fiscal year at the latest. In addition, battery systems for mass-market applications such as pedelecs and e-bikes contributed to revenue for the first time in the third quarter.
*Focus on Integrating Acquisitions *
Following its acquisition of ACCURATE Smart Battery Systems, Voltabox has completed its M&A growth for the time being. As previously announced as of the company's IPO, through its latest purchase, Voltabox will also be able to tap into selected high-margin mass markets for lithium-ion battery systems. ACCURATE develops and produces tailor-made, standardized battery systems for pedelecs and e-bikes, particularly in the premium segment. ACCURATE's solutions are also attractive for other high-growth mass markets which Voltabox aims to gradually tap into.
The closing of the acquisition of Navitas Systems is still subject to the condition precedent of approval from the American authorities for the overall transaction. Due to the delay of the execution, the purchase price has been revised - Voltabox will now pay around USD 41.5 million (equivalent to about EUR 35.7 million) for Navitas instead of the original amount of USD 43 million (equivalent to around EUR 37 million). In addition, the parties have agreed to a payment of the purchase price in four yearly installments, the largest of which will become due upon execution of the contract. Currently, the Management Board expects approval from the US authorities in the near future, so that the entire transaction can be executed in November.
*High Total Operating Performance Thanks to Stockpiling of Finished Goods and Work in Progress *
Due to the higher production volumes, the cost of materials increased by 122.2 % to EUR 23.9 million (prior year: EUR 10.8 million). The cost of materials ratio (calculated from the ratio of cost of materials to sales and changes in inventories) fell to 57.9 % (previous year: 63.8 %) primarily as a result of economies of scale. In the context of this high total operating performance, a gross profit for the period under review resulted in the amount of EUR 22.1 million (prior year: EUR 9.2 million), which constitutes a gross profit margin of 66.1 % (prior year: 56.2 %). Mainly as a result of the new hires in connection with the operational growth as well as the acquisitions, personnel costs increased by 97.1 % to EUR 8.8 million (prior year: EUR 4.5 million). The personnel expense ratio decreased slightly to 26.2 % (prior year: 27.3 %). The number of employees increased from 94 to 193 in the first nine months of the year.
*Profit After Tax Achieved for the First Time*
Earnings before interest, taxes, depreciation and amortization (EBITDA) rose considerably to EUR 4.9 million (prior year: EUR -0.3 million), which corresponds to an EBITDA margin of 14.8 % (prior year: -1.5 %). After an expected increase in depreciation and amortization totaling EUR 2.6 million (prior year: EUR 1.5 million), earnings before interest and taxes (EBIT) improved to EUR 2.3 million (prior year: EUR -1.8 million). Accounting for the considerable increase in revenue, the EBIT margin rose clearly to 7.0 % (prior year: -10.7 %). Given that net finance costs improved slightly to EUR -0.4 million (prior year: EUR -0.5 million) while income tax expenses amounted to EUR 0.1 million (prior year: EUR 0.7 million in income, mainly due to the change in deferred tax assets), in the period under review consolidated net income increased to EUR 1.8 million (prior year: EUR -1.5 million). This corresponds to earnings per share of EUR 0.11.
*Net Assets and Financial Position Remain Very Solid*
Noncurrent assets increased by EUR 15.2 million to EUR 46.3 million (December 31, 2017: EUR 31.1 million). In particular, this is due to the EUR 7.3 million increase in intangible assets to EUR 23.8 million (December 31, 2017: EUR 16.5 million) as well as the increase in goodwill to EUR 9.7 million due to the consolidation of Concurrent Design and ACCURATE (December 31, 2017: EUR 3.2 million).
Current assets decreased to EUR 130.0 million (December 31, 2017: EUR 139.6 million). Inventories rose by EUR 13.5 million to EUR 17.7 million and trade receivables by EUR 16.9 million to EUR 39.0 million. These increases were attributable to expanded business activities as well as the payment periods extended for the current year for the company's customer Triathlon, for the purpose of its sales financing. Other assets rose by EUR 7.9 million to EUR 8.1 million in the second quarter in particular, due to the early restructuring of the cooperation agreement with Triathlon (mainly on account of capitalization of the one-time investment contribution for capacity expansion). At the same time, cash and cash equivalents decreased by EUR 46.8 million to EUR 55.8 million (December 31, 2017: EUR 102.7 million). The decline in the third quarter was mainly due to operating expenses in connection with dynamic growth in the market for intralogistics and also the acquisition of ACCURATE.
*Strong Equity Ratio of 89 percent*
Voltabox AG's equity amounts to EUR 157.1 million (December 31, 2017: 155.0 million) The equity ratio decreased marginally to 89.1 % (December 31, 2017: 90.8 %) as of the balance sheet date due to the slightly higher balance sheet total.
Cash flow from operating activities decreased significantly in the period under review to EUR -30.1 million (prior year: EUR -6.4 million). This was mainly a result of the significant increase in trade receivables of EUR 23.7 million (prior year: EUR 3.1 million) as well as higher inventories of EUR 13.5 million (prior year: EUR 1.8 million).
Cash flow from investing activities decreased by EUR 13.1 million to EUR -16.3 million in the period under review (prior year: EUR -3.2 million). This was mainly due to payments for investments in property, plant and equipment in the amount of EUR 1.1 million, payments for investments in intangible assets in the amount of EUR 6.6 million as well as payments resulting from the acquisition of consolidated companies and other business units, specifically the purchase price payments for ACCURATE Smart Battery Systems GmbH and Concurrent Design, Inc., in the amount of EUR 8.7 million.
Cash and cash equivalents totaled EUR 55.8 million as of the end of the reporting period (December 31, 2017: EUR 102.7 million).
*Management Board Confirms Forecast for Revenue and Profitability*
In view of the positive order situation, the Management Board expects that Voltabox will experience growth in its existing market segments that clearly outstrips the rest of the market, along with increasing profitability. In addition to intralogistics, the trolleybus and agricultural and construction market segments will be key growth drivers. The revenue forecast of EUR 65 million to EUR 70 million for fiscal year 2018 is confirmed, as is the outlook for operating profitability. However, the strategically important restructuring of the partnership with Triathlon in order to hedge the market leadership that the company seeks in the intralogistics growth market is burdening EBIT in the current fiscal year by about EUR 2 million. An EBIT margin of around 7 % is therefore envisaged for the year as a whole, as was indicated in the half-year report.
The Management Board expects to see an investment volume of around EUR 13.4 million in the current year. Own work capitalized should amount to around 43 % of the investment total for the current year.
The interim report and condensed consolidated financial statements as of September 30, 2018, are available for download at http://ir.voltabox.ag.*About Voltabox AG*
Voltabox AG (ISIN DE000A2E4LE9), which is listed on the regulated market (Prime Standard) of the Frankfurt Stock Exchange, is a rapidly growing system provider for e-mobility in industrial applications. Its core business lies in intrinsically safe, highly developed high-performance lithium-ion batteries that are modular and in serial production. The battery systems are primarily used in buses for public transportation, forklifts, automated guided vehicles and mining vehicles. The company also develops and produces high-quality lithium-ion batteries for select mass-market applications, such as high-performance motorcycles and pedelecs.
Voltabox has production sites at its headquarters in Delbrück, Germany, in Austin, Texas, USA, and in Kunshan, China, as well as a development sites in Aachen and Korntal-Münchingen, Germany.
Additional information about Voltabox can be found at www.voltabox.ag.*Financial Presse and Investor Relations Contact*
*Voltabox AG *
Dr. Kai Holtmann
Artegastraße 1
D-33129 Delbrück
Phone: +49 (0) 52 50 - 99 30-964
Fax: +49 (0) 52 50 - 99 30-901
Email: investor@voltabox.ag
--------------------
13.11.2018 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de --------------------
Language: English
Company: Voltabox AG
Artegastraße 1
33129 Delbrück
Germany
Phone: +49 (0)5250 9930 964
Fax: +49 (0)5250 9930 901
E-mail: info@voltabox.ag
Internet: www.voltabox.ag
ISIN: DE000A2E4LE9
WKN: A2E4LE
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
End of News DGAP News Service Reported by EQS Group 4 hours ago.
13.11.2018 / 07:30
The issuer is solely responsible for the content of this announcement.
--------------------
*Voltabox Doubles Revenue in First Nine Months of the Year With Increasing Profitability - Forecast for the Year as a Whole Confirmed*
*- Group sales double to EUR 33.5 million*
*- Increasing market penetration in intralogistics results in high level of utilization*
*- EBITDA grows from EUR -0.3 million in the prior year to EUR 4.9 million*
*- EBIT increases to EUR 2.3 million; EBIT margin improves considerably to 7.0 percent*
*- Number of employees doubles to 193 in the first nine months of the year*
*- Forecast for 2018 confirmed: revenue of EUR 65-70 million with an EBIT margin of about 7 percent*
*Delbrück, Germany, November 13, 2018 *- Voltabox AG [ISIN DE000A2E4LE9] published its results for the first nine months of 2018 today and confirmed its forecast for the year as a whole.
"*Our focus on lucrative e-mobility niche markets is beginning to pay off," says Jürgen Pampel, Chief Executive Officer of Voltabox AG. "Especially in the area of intralogistics, there is a very strong level of demand for our technology. We had an accordingly high level of utilization in the highly automated field of modules production in the third quarter. A significant part of this increased demand is attributable to our cooperation with our partner Triathlon, which we relaunched in the second quarter. We are also benefiting from our direct market access in the area of intralogistics."*
Thanks to the further rise in demand, Voltabox achieved revenue of EUR 15.4 million in the third quarter. The increase in the inventory of finished goods and work in progress should also be included in an assessment of the company's total operating performance. The former amounts to EUR 7.2 million and is mainly attributable to inventory build-up of modules produced for use in forklifts and other intralogistics applications. In the period from January to September, Voltabox generated revenue of EUR 33.5 million and thus grew by 105 percent over the prior year (EUR 16.3 million). The EBIT margin also increased very strongly year-over-year and amounted to 7.0 percent for the first nine months of the year (prior year: -10.7 percent).
*Modules for Intralogistics and Battery Systems for Trolleybuses Shape Revenue Growth*
In addition to large quantities of battery modules for intralogistics, Voltabox produced battery systems for use in trolleybuses in the third quarter. These are intended for the local public transport grids of Seattle, San Francisco and Lucerne. Voltabox also serially produced and delivered the first battery systems for Schäffer, a compact-, wheel- and teleloader provider, in the third quarter. It's the company's intention to at least maintain the same level of production output in the fourth quarter. At the same time, series production of starter batteries for BMW Motorrad is now finally set to begin. This should be reflected in additional revenue at the start of the coming fiscal year at the latest. In addition, battery systems for mass-market applications such as pedelecs and e-bikes contributed to revenue for the first time in the third quarter.
*Focus on Integrating Acquisitions *
Following its acquisition of ACCURATE Smart Battery Systems, Voltabox has completed its M&A growth for the time being. As previously announced as of the company's IPO, through its latest purchase, Voltabox will also be able to tap into selected high-margin mass markets for lithium-ion battery systems. ACCURATE develops and produces tailor-made, standardized battery systems for pedelecs and e-bikes, particularly in the premium segment. ACCURATE's solutions are also attractive for other high-growth mass markets which Voltabox aims to gradually tap into.
The closing of the acquisition of Navitas Systems is still subject to the condition precedent of approval from the American authorities for the overall transaction. Due to the delay of the execution, the purchase price has been revised - Voltabox will now pay around USD 41.5 million (equivalent to about EUR 35.7 million) for Navitas instead of the original amount of USD 43 million (equivalent to around EUR 37 million). In addition, the parties have agreed to a payment of the purchase price in four yearly installments, the largest of which will become due upon execution of the contract. Currently, the Management Board expects approval from the US authorities in the near future, so that the entire transaction can be executed in November.
*High Total Operating Performance Thanks to Stockpiling of Finished Goods and Work in Progress *
Due to the higher production volumes, the cost of materials increased by 122.2 % to EUR 23.9 million (prior year: EUR 10.8 million). The cost of materials ratio (calculated from the ratio of cost of materials to sales and changes in inventories) fell to 57.9 % (previous year: 63.8 %) primarily as a result of economies of scale. In the context of this high total operating performance, a gross profit for the period under review resulted in the amount of EUR 22.1 million (prior year: EUR 9.2 million), which constitutes a gross profit margin of 66.1 % (prior year: 56.2 %). Mainly as a result of the new hires in connection with the operational growth as well as the acquisitions, personnel costs increased by 97.1 % to EUR 8.8 million (prior year: EUR 4.5 million). The personnel expense ratio decreased slightly to 26.2 % (prior year: 27.3 %). The number of employees increased from 94 to 193 in the first nine months of the year.
*Profit After Tax Achieved for the First Time*
Earnings before interest, taxes, depreciation and amortization (EBITDA) rose considerably to EUR 4.9 million (prior year: EUR -0.3 million), which corresponds to an EBITDA margin of 14.8 % (prior year: -1.5 %). After an expected increase in depreciation and amortization totaling EUR 2.6 million (prior year: EUR 1.5 million), earnings before interest and taxes (EBIT) improved to EUR 2.3 million (prior year: EUR -1.8 million). Accounting for the considerable increase in revenue, the EBIT margin rose clearly to 7.0 % (prior year: -10.7 %). Given that net finance costs improved slightly to EUR -0.4 million (prior year: EUR -0.5 million) while income tax expenses amounted to EUR 0.1 million (prior year: EUR 0.7 million in income, mainly due to the change in deferred tax assets), in the period under review consolidated net income increased to EUR 1.8 million (prior year: EUR -1.5 million). This corresponds to earnings per share of EUR 0.11.
*Net Assets and Financial Position Remain Very Solid*
Noncurrent assets increased by EUR 15.2 million to EUR 46.3 million (December 31, 2017: EUR 31.1 million). In particular, this is due to the EUR 7.3 million increase in intangible assets to EUR 23.8 million (December 31, 2017: EUR 16.5 million) as well as the increase in goodwill to EUR 9.7 million due to the consolidation of Concurrent Design and ACCURATE (December 31, 2017: EUR 3.2 million).
Current assets decreased to EUR 130.0 million (December 31, 2017: EUR 139.6 million). Inventories rose by EUR 13.5 million to EUR 17.7 million and trade receivables by EUR 16.9 million to EUR 39.0 million. These increases were attributable to expanded business activities as well as the payment periods extended for the current year for the company's customer Triathlon, for the purpose of its sales financing. Other assets rose by EUR 7.9 million to EUR 8.1 million in the second quarter in particular, due to the early restructuring of the cooperation agreement with Triathlon (mainly on account of capitalization of the one-time investment contribution for capacity expansion). At the same time, cash and cash equivalents decreased by EUR 46.8 million to EUR 55.8 million (December 31, 2017: EUR 102.7 million). The decline in the third quarter was mainly due to operating expenses in connection with dynamic growth in the market for intralogistics and also the acquisition of ACCURATE.
*Strong Equity Ratio of 89 percent*
Voltabox AG's equity amounts to EUR 157.1 million (December 31, 2017: 155.0 million) The equity ratio decreased marginally to 89.1 % (December 31, 2017: 90.8 %) as of the balance sheet date due to the slightly higher balance sheet total.
Cash flow from operating activities decreased significantly in the period under review to EUR -30.1 million (prior year: EUR -6.4 million). This was mainly a result of the significant increase in trade receivables of EUR 23.7 million (prior year: EUR 3.1 million) as well as higher inventories of EUR 13.5 million (prior year: EUR 1.8 million).
Cash flow from investing activities decreased by EUR 13.1 million to EUR -16.3 million in the period under review (prior year: EUR -3.2 million). This was mainly due to payments for investments in property, plant and equipment in the amount of EUR 1.1 million, payments for investments in intangible assets in the amount of EUR 6.6 million as well as payments resulting from the acquisition of consolidated companies and other business units, specifically the purchase price payments for ACCURATE Smart Battery Systems GmbH and Concurrent Design, Inc., in the amount of EUR 8.7 million.
Cash and cash equivalents totaled EUR 55.8 million as of the end of the reporting period (December 31, 2017: EUR 102.7 million).
*Management Board Confirms Forecast for Revenue and Profitability*
In view of the positive order situation, the Management Board expects that Voltabox will experience growth in its existing market segments that clearly outstrips the rest of the market, along with increasing profitability. In addition to intralogistics, the trolleybus and agricultural and construction market segments will be key growth drivers. The revenue forecast of EUR 65 million to EUR 70 million for fiscal year 2018 is confirmed, as is the outlook for operating profitability. However, the strategically important restructuring of the partnership with Triathlon in order to hedge the market leadership that the company seeks in the intralogistics growth market is burdening EBIT in the current fiscal year by about EUR 2 million. An EBIT margin of around 7 % is therefore envisaged for the year as a whole, as was indicated in the half-year report.
The Management Board expects to see an investment volume of around EUR 13.4 million in the current year. Own work capitalized should amount to around 43 % of the investment total for the current year.
The interim report and condensed consolidated financial statements as of September 30, 2018, are available for download at http://ir.voltabox.ag.*About Voltabox AG*
Voltabox AG (ISIN DE000A2E4LE9), which is listed on the regulated market (Prime Standard) of the Frankfurt Stock Exchange, is a rapidly growing system provider for e-mobility in industrial applications. Its core business lies in intrinsically safe, highly developed high-performance lithium-ion batteries that are modular and in serial production. The battery systems are primarily used in buses for public transportation, forklifts, automated guided vehicles and mining vehicles. The company also develops and produces high-quality lithium-ion batteries for select mass-market applications, such as high-performance motorcycles and pedelecs.
Voltabox has production sites at its headquarters in Delbrück, Germany, in Austin, Texas, USA, and in Kunshan, China, as well as a development sites in Aachen and Korntal-Münchingen, Germany.
Additional information about Voltabox can be found at www.voltabox.ag.*Financial Presse and Investor Relations Contact*
*Voltabox AG *
Dr. Kai Holtmann
Artegastraße 1
D-33129 Delbrück
Phone: +49 (0) 52 50 - 99 30-964
Fax: +49 (0) 52 50 - 99 30-901
Email: investor@voltabox.ag
--------------------
13.11.2018 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de --------------------
Language: English
Company: Voltabox AG
Artegastraße 1
33129 Delbrück
Germany
Phone: +49 (0)5250 9930 964
Fax: +49 (0)5250 9930 901
E-mail: info@voltabox.ag
Internet: www.voltabox.ag
ISIN: DE000A2E4LE9
WKN: A2E4LE
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
End of News DGAP News Service Reported by EQS Group 4 hours ago.
↧
paragon Increases Revenue by 40 Percent in Period up to September - Forecast for the Year as a Whole Confirmed
DGAP-News: paragon GmbH & Co. KGaA / Key word(s): Interim Report
13.11.2018 / 07:30
The issuer is solely responsible for the content of this announcement.
--------------------
*paragon Increases Revenue by 40 Percent in Period up to September - Forecast for the Year as a Whole Confirmed*
*- Group sales for first three quarters of the year up by 40.2 percent to EUR 118.8 million; revenue from automotive manufacturers increases by around 20 percent*
*- Revenue of the new Body Kinematics and Electromobility business units almost tripled; share of Group sales doubled to 46.9 percent*
*- EBITDA increases by 36.3 percent to EUR 17.2 million*
*- EBIT margin amounts to 6.5 percent*
*- Revenue and EBIT forecasts for 2018 confirmed*
*Delbrück, Germany, November 13, 2018 - *paragon GmbH & Co. KGaA [ISIN DE0005558696] published its condensed interim financial statements as of September 30, 2018, as well as its outlook for the year as a whole today.
*"We develop highly specific, independent technology solutions for German and foreign automotive manufacturers. This means we are far less sensitive to economic trends than other automotive suppliers," says Klaus Dieter Frers, founder and Chairman of the Board of paragon GmbH, the personally liable general partner of paragon GmbH & Co. KGaA. "However, on the capital market we are nonetheless lumped in together with the rest of the automotive supplier industry. The negative assessment of our automotive business is not plausible, since current issues such as WLTP, the diesel problem and trade conflicts have had virtually no impact on us. The stock exchange is now valuing paragon's majority stake in Voltabox higher than the paragon Group as a whole. Our equity is around EUR 55 million higher than our current market capitalization. However, we will not allow this market distortion to distract us from our clear strategy. Through our latest acquisitions, we will penetrate the digital segment of the automotive value chain even more strongly and realize new growth potential. At the same time, through Voltabox we are occupying attractive niche markets for e-mobility."*
paragon generated revenue of EUR 40.2 million in the third quarter (prior year: EUR 29.4 million) and thus remains on track for fiscal year 2018. In the final quarter of the year, which is now underway, the company expects the usual pick-up in order volumes from its customers for this period. Deliveries are expected to increase significantly in the Electromobility operating segment in particular.
The third quarter was shaped by several acquisitions through which paragon will increase its added value in the automotive industry's digital and e-mobility-based future. Through its acquisition of SemVox (now: paragon semvox GmbH), paragon has won 10 years of development time in the field of artificial intelligence. SemVox's technology is already integrated in various vehicles and is around three years ahead of similar solutions, including those of major American providers. paragon semvox GmbH is the new "Digital Assistance" business unit of paragon GmbH & Co. KGaA. New product generations at the system level will help to shape the digital future of the automotive industry.
paragon is pursuing a similar objective through its acquisition of LPG. As well as tweeters and cone loudspeakers, this company develops and produces internal and external speakers whose configurable signals make it easier for other road users to notice electric vehicles. paragon is thus expanding its technology base for acoustics solutions and its value chain. The system components of LPG (now: paragon electroacoustic GmbH) represent an important aspect of the company's Interior business unit, which will combine the current Cockpit and Acoustics business units in future.
*New Business Units Drive Revenue Trend*
In the first three quarters of the year, Group sales amounted to EUR 118.8 million (prior year: EUR 84.7 million) and were thus 40.2% higher than in the previous year. The increase in the inventory of finished goods and work in progress of EUR 9.3 million (prior year: EUR 1.1 million) is primarily attributable to expanded business activities in the Electromobility operating segment and chiefly comprises completed modules for use in forklifts and other intralogistics applications.
Development costs capitalized were up as expected by 37.4% to EUR 14.5 million (prior year: EUR 10.6 million). They were equally attributable to all three of the operating segments. Due to the expanded volume of production in the new business units (especially increase in inventory of finished goods and work in progress at Voltabox AG), the cost of materials increased by 59.6% to EUR 72.7 million (prior year: EUR 45.6 million). The cost of materials ratio (calculated from the ratio of cost of materials to sales and changes in inventories) amounted to 56.4% (previous year 52.7%). This increase is mainly due to the higher sales contribution of paragon movasys GmbH, whose cost of materials ratio is still higher than the average cost of materials ratio in the Group. In addition, the share of development revenues in the Cockpit division was lower than in the previous year. At the same time, the cost of materials ratio in the Electromobility segment decreased due to economies of scale. This corresponds to a gross profit for the first nine months of EUR 70.6 million (prior year: EUR 51.5 million), which represents a gross profit margin of 59.4% (prior year: 60.8%). The number of employees increased by one quarter to 847 (December 31, 2017: 678).
*Profitability on Track*
Earnings before interest, taxes, depreciation and amortization (EBITDA) rose 36.3% to EUR 17.2 million (prior year: EUR 12.6 million), which corresponds to an EBITDA margin of 14.5% (prior year: 14.9%). After an expected increase in depreciation and amortization totaling EUR 9.5 million (prior year: EUR 6.5 million), earnings before interest and taxes (EBIT) improved by 25.4% to EUR 7.7 million (prior year: EUR 6.1 million). The EBIT margin decreased as scheduled to 6.5% (prior year: 7.2%).
With a financial result of EUR -3.9 million (prior year: EUR -2.9 million) and income taxes of EUR 1.9 million (prior year: EUR 1.1 million), paragon generated a consolidated income of EUR 2.0 million in the period under review (prior year: EUR 2.1 million). This corresponds to earnings per share of EUR 0.43 (prior year: EUR 0.47). Minority interests accounted for EUR 0.7 million.
As of September 30, 2018, total assets increased by EUR 19.2 million to EUR 331.0 million (December 31, 2017: EUR 311.8 million), which is mainly attributable to the increase in financial assets as well as intangible assets and goodwill.
*Cash Flow Reflects Growth Strategy*
The equity of paragon GmbH & Co. KGaA increased only marginally to EUR 178.2 million (December 31, 2017: EUR 177.0 million). Given the slight increase in total assets, as of the end of the reporting period the equity ratio decreased to 53.8% (December 31, 2017: 56.8%).
Cash flow from operating activities declined in the period under review by EUR 32.2 million to EUR -35.4 million (prior year: EUR -3.2 million). The main reasons for this were the EUR 17.0 million higher increase in trade receivables to EUR 25.0 million, due to the sales financing of an important customer by Voltabox, and the EUR 23.3 million higher increase in inventories to EUR 27.9 million. At the same time, trade payables and other liabilities increased by EUR 5.4 million in the period under review, having declined by EUR 1.9 million in the prior year. Finally, depreciation of noncurrent assets increased by EUR 2.9 million to EUR 9.4 million.
Cash flow from investing activities decreased by EUR 40.7 million to EUR -53.5 million in the period under review (prior year: EUR -12.9 million). This was mainly due to a EUR 6.7 million increase in payments for investments in property, plant and equipment to the current EUR 8.3 million (prior year: EUR 1.6 million), a EUR 5.6 million increase in payments for investments in intangible assets to EUR 16.6 million and payments for investments in financial assets in the amount of EUR 19.9 million for the acquisition of SemVox. In addition, payments resulting from the acquisition of consolidated companies and other business units increased by EUR 7.9 million to EUR 8.7 million due to the acquisitions of Concurrent Design and ACCURATE.
Cash and cash equivalents totaled EUR 65.1 million as of the end of the reporting period (prior year: EUR 33.8 million).
*Forecast Confirmed in Challenging Market Environment*
On the basis of the good order situation, paragon expects, as forecast, to once more grow significantly faster than the automotive sector in fiscal year 2018. However, due to paragon's specific product-customer mix, management does not consider that the current challenges facing the automotive industry will pose any additional risks to its further economic development in the current fiscal year.
In view of Voltabox AG's robust order backlog for fiscal year 2018, management is expecting a significantly higher growth rate in the Electromobility operating segment. Voltabox has confirmed its revenue forecast for the current fiscal year in the amount of EUR 65-70 million. The Body Kinematics business unit should also make a particularly strong contribution to growth; the company expects the organizational measures that have been taken to provide synergy effects here totaling EUR 3-5 million over the course of the next three years. From fiscal year 2019 onwards, the Electronics operating segment is expected to provide a stronger contribution to the Group's growth through new products and acquisitions.
For fiscal year 2018, paragon's management confirms its revenue forecast of EUR 180-185 million. An EBIT margin of around 8% is still expected. Voltabox's restructuring of its agreement with Triathlon in the second half of 2018 has already been factored in here. This will burden EBIT in the current fiscal year by around EUR 2 million. An investment volume of around EUR 35 million is expected for the year as a whole.
The Group interim report and the condensed interim financial statements as of September 30, 2018, are available for download at ir.paragon.ag.
*About paragon GmbH & Co. KGaA*
paragon GmbH & Co. KGaA (ISIN DE0005558696), which is listed in the regulated market (Prime Standard) of the Frankfurt Stock Exchange, develops, produces and distributes forward-looking solutions in the field of automotive electronics, body kinematics and e-mobility. As a market-leading direct supplier to the automotive industry, the company's portfolio includes the Electronics operating segment's innovative air-quality management, state-of-the-art display systems and connectivity solutions, and high-end acoustic systems. In the Mechanics operating segment, paragon develops and produces active mobile aerodynamic systems. With Voltabox AG (ISIN DE000A2E4LE9), a subsidiary that is also listed on the regulated market (Prime Standard) of the Frankfurt Stock Exchange, the Group is also active in the rapidly growing Electromobility operating segment with its cutting-edge lithium-ion battery systems developed in-house.
In addition to the company headquarters in Delbrück (North Rhine-Westphalia, Germany), paragon GmbH & Co. KGaA and its subsidiaries operate sites in Suhl (Thuringia, Germany), Landsberg am Lech, Neu-Ulm and Nuremberg (Bavaria, Germany), Korntal-Münchingen and St. Georgen (Baden-Württemberg, Germany), Bexbach and Saarbrücken (Saarland, Germany) and Aachen (North Rhine-Westphalia, Germany) as well as in Kunshan (China) and Austin, Texas (USA).
Additional information about paragon can be found at www.paragon.ag.
*Financial Press & Investor Relations Contact*
*paragon GmbH & Co. KGaA*
Dr. Kai Holtmann
Artegastrasse 1
33129 Delbrück, Germany
Phone: +49 (0) 52 50 - 97 62-140
Fax: +49 (0) 52 50 - 97 62-63
Email: investor@paragon.ag
--------------------
13.11.2018 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de --------------------
Language: English
Company: paragon GmbH & Co. KGaA
Artegastraße 1
33129 Delbrück
Germany
Phone: +49 (0)5250 97 62 - 0
Fax: +49 (0)5250 97 62 - 60
E-mail: investor@paragon.ag
Internet: www.paragon.ag
ISIN: DE0005558696, DE000A2GSB86,
WKN: 555869, A2GSB8,
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
End of News DGAP News Service Reported by EQS Group 4 hours ago.
13.11.2018 / 07:30
The issuer is solely responsible for the content of this announcement.
--------------------
*paragon Increases Revenue by 40 Percent in Period up to September - Forecast for the Year as a Whole Confirmed*
*- Group sales for first three quarters of the year up by 40.2 percent to EUR 118.8 million; revenue from automotive manufacturers increases by around 20 percent*
*- Revenue of the new Body Kinematics and Electromobility business units almost tripled; share of Group sales doubled to 46.9 percent*
*- EBITDA increases by 36.3 percent to EUR 17.2 million*
*- EBIT margin amounts to 6.5 percent*
*- Revenue and EBIT forecasts for 2018 confirmed*
*Delbrück, Germany, November 13, 2018 - *paragon GmbH & Co. KGaA [ISIN DE0005558696] published its condensed interim financial statements as of September 30, 2018, as well as its outlook for the year as a whole today.
*"We develop highly specific, independent technology solutions for German and foreign automotive manufacturers. This means we are far less sensitive to economic trends than other automotive suppliers," says Klaus Dieter Frers, founder and Chairman of the Board of paragon GmbH, the personally liable general partner of paragon GmbH & Co. KGaA. "However, on the capital market we are nonetheless lumped in together with the rest of the automotive supplier industry. The negative assessment of our automotive business is not plausible, since current issues such as WLTP, the diesel problem and trade conflicts have had virtually no impact on us. The stock exchange is now valuing paragon's majority stake in Voltabox higher than the paragon Group as a whole. Our equity is around EUR 55 million higher than our current market capitalization. However, we will not allow this market distortion to distract us from our clear strategy. Through our latest acquisitions, we will penetrate the digital segment of the automotive value chain even more strongly and realize new growth potential. At the same time, through Voltabox we are occupying attractive niche markets for e-mobility."*
paragon generated revenue of EUR 40.2 million in the third quarter (prior year: EUR 29.4 million) and thus remains on track for fiscal year 2018. In the final quarter of the year, which is now underway, the company expects the usual pick-up in order volumes from its customers for this period. Deliveries are expected to increase significantly in the Electromobility operating segment in particular.
The third quarter was shaped by several acquisitions through which paragon will increase its added value in the automotive industry's digital and e-mobility-based future. Through its acquisition of SemVox (now: paragon semvox GmbH), paragon has won 10 years of development time in the field of artificial intelligence. SemVox's technology is already integrated in various vehicles and is around three years ahead of similar solutions, including those of major American providers. paragon semvox GmbH is the new "Digital Assistance" business unit of paragon GmbH & Co. KGaA. New product generations at the system level will help to shape the digital future of the automotive industry.
paragon is pursuing a similar objective through its acquisition of LPG. As well as tweeters and cone loudspeakers, this company develops and produces internal and external speakers whose configurable signals make it easier for other road users to notice electric vehicles. paragon is thus expanding its technology base for acoustics solutions and its value chain. The system components of LPG (now: paragon electroacoustic GmbH) represent an important aspect of the company's Interior business unit, which will combine the current Cockpit and Acoustics business units in future.
*New Business Units Drive Revenue Trend*
In the first three quarters of the year, Group sales amounted to EUR 118.8 million (prior year: EUR 84.7 million) and were thus 40.2% higher than in the previous year. The increase in the inventory of finished goods and work in progress of EUR 9.3 million (prior year: EUR 1.1 million) is primarily attributable to expanded business activities in the Electromobility operating segment and chiefly comprises completed modules for use in forklifts and other intralogistics applications.
Development costs capitalized were up as expected by 37.4% to EUR 14.5 million (prior year: EUR 10.6 million). They were equally attributable to all three of the operating segments. Due to the expanded volume of production in the new business units (especially increase in inventory of finished goods and work in progress at Voltabox AG), the cost of materials increased by 59.6% to EUR 72.7 million (prior year: EUR 45.6 million). The cost of materials ratio (calculated from the ratio of cost of materials to sales and changes in inventories) amounted to 56.4% (previous year 52.7%). This increase is mainly due to the higher sales contribution of paragon movasys GmbH, whose cost of materials ratio is still higher than the average cost of materials ratio in the Group. In addition, the share of development revenues in the Cockpit division was lower than in the previous year. At the same time, the cost of materials ratio in the Electromobility segment decreased due to economies of scale. This corresponds to a gross profit for the first nine months of EUR 70.6 million (prior year: EUR 51.5 million), which represents a gross profit margin of 59.4% (prior year: 60.8%). The number of employees increased by one quarter to 847 (December 31, 2017: 678).
*Profitability on Track*
Earnings before interest, taxes, depreciation and amortization (EBITDA) rose 36.3% to EUR 17.2 million (prior year: EUR 12.6 million), which corresponds to an EBITDA margin of 14.5% (prior year: 14.9%). After an expected increase in depreciation and amortization totaling EUR 9.5 million (prior year: EUR 6.5 million), earnings before interest and taxes (EBIT) improved by 25.4% to EUR 7.7 million (prior year: EUR 6.1 million). The EBIT margin decreased as scheduled to 6.5% (prior year: 7.2%).
With a financial result of EUR -3.9 million (prior year: EUR -2.9 million) and income taxes of EUR 1.9 million (prior year: EUR 1.1 million), paragon generated a consolidated income of EUR 2.0 million in the period under review (prior year: EUR 2.1 million). This corresponds to earnings per share of EUR 0.43 (prior year: EUR 0.47). Minority interests accounted for EUR 0.7 million.
As of September 30, 2018, total assets increased by EUR 19.2 million to EUR 331.0 million (December 31, 2017: EUR 311.8 million), which is mainly attributable to the increase in financial assets as well as intangible assets and goodwill.
*Cash Flow Reflects Growth Strategy*
The equity of paragon GmbH & Co. KGaA increased only marginally to EUR 178.2 million (December 31, 2017: EUR 177.0 million). Given the slight increase in total assets, as of the end of the reporting period the equity ratio decreased to 53.8% (December 31, 2017: 56.8%).
Cash flow from operating activities declined in the period under review by EUR 32.2 million to EUR -35.4 million (prior year: EUR -3.2 million). The main reasons for this were the EUR 17.0 million higher increase in trade receivables to EUR 25.0 million, due to the sales financing of an important customer by Voltabox, and the EUR 23.3 million higher increase in inventories to EUR 27.9 million. At the same time, trade payables and other liabilities increased by EUR 5.4 million in the period under review, having declined by EUR 1.9 million in the prior year. Finally, depreciation of noncurrent assets increased by EUR 2.9 million to EUR 9.4 million.
Cash flow from investing activities decreased by EUR 40.7 million to EUR -53.5 million in the period under review (prior year: EUR -12.9 million). This was mainly due to a EUR 6.7 million increase in payments for investments in property, plant and equipment to the current EUR 8.3 million (prior year: EUR 1.6 million), a EUR 5.6 million increase in payments for investments in intangible assets to EUR 16.6 million and payments for investments in financial assets in the amount of EUR 19.9 million for the acquisition of SemVox. In addition, payments resulting from the acquisition of consolidated companies and other business units increased by EUR 7.9 million to EUR 8.7 million due to the acquisitions of Concurrent Design and ACCURATE.
Cash and cash equivalents totaled EUR 65.1 million as of the end of the reporting period (prior year: EUR 33.8 million).
*Forecast Confirmed in Challenging Market Environment*
On the basis of the good order situation, paragon expects, as forecast, to once more grow significantly faster than the automotive sector in fiscal year 2018. However, due to paragon's specific product-customer mix, management does not consider that the current challenges facing the automotive industry will pose any additional risks to its further economic development in the current fiscal year.
In view of Voltabox AG's robust order backlog for fiscal year 2018, management is expecting a significantly higher growth rate in the Electromobility operating segment. Voltabox has confirmed its revenue forecast for the current fiscal year in the amount of EUR 65-70 million. The Body Kinematics business unit should also make a particularly strong contribution to growth; the company expects the organizational measures that have been taken to provide synergy effects here totaling EUR 3-5 million over the course of the next three years. From fiscal year 2019 onwards, the Electronics operating segment is expected to provide a stronger contribution to the Group's growth through new products and acquisitions.
For fiscal year 2018, paragon's management confirms its revenue forecast of EUR 180-185 million. An EBIT margin of around 8% is still expected. Voltabox's restructuring of its agreement with Triathlon in the second half of 2018 has already been factored in here. This will burden EBIT in the current fiscal year by around EUR 2 million. An investment volume of around EUR 35 million is expected for the year as a whole.
The Group interim report and the condensed interim financial statements as of September 30, 2018, are available for download at ir.paragon.ag.
*About paragon GmbH & Co. KGaA*
paragon GmbH & Co. KGaA (ISIN DE0005558696), which is listed in the regulated market (Prime Standard) of the Frankfurt Stock Exchange, develops, produces and distributes forward-looking solutions in the field of automotive electronics, body kinematics and e-mobility. As a market-leading direct supplier to the automotive industry, the company's portfolio includes the Electronics operating segment's innovative air-quality management, state-of-the-art display systems and connectivity solutions, and high-end acoustic systems. In the Mechanics operating segment, paragon develops and produces active mobile aerodynamic systems. With Voltabox AG (ISIN DE000A2E4LE9), a subsidiary that is also listed on the regulated market (Prime Standard) of the Frankfurt Stock Exchange, the Group is also active in the rapidly growing Electromobility operating segment with its cutting-edge lithium-ion battery systems developed in-house.
In addition to the company headquarters in Delbrück (North Rhine-Westphalia, Germany), paragon GmbH & Co. KGaA and its subsidiaries operate sites in Suhl (Thuringia, Germany), Landsberg am Lech, Neu-Ulm and Nuremberg (Bavaria, Germany), Korntal-Münchingen and St. Georgen (Baden-Württemberg, Germany), Bexbach and Saarbrücken (Saarland, Germany) and Aachen (North Rhine-Westphalia, Germany) as well as in Kunshan (China) and Austin, Texas (USA).
Additional information about paragon can be found at www.paragon.ag.
*Financial Press & Investor Relations Contact*
*paragon GmbH & Co. KGaA*
Dr. Kai Holtmann
Artegastrasse 1
33129 Delbrück, Germany
Phone: +49 (0) 52 50 - 97 62-140
Fax: +49 (0) 52 50 - 97 62-63
Email: investor@paragon.ag
--------------------
13.11.2018 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de --------------------
Language: English
Company: paragon GmbH & Co. KGaA
Artegastraße 1
33129 Delbrück
Germany
Phone: +49 (0)5250 97 62 - 0
Fax: +49 (0)5250 97 62 - 60
E-mail: investor@paragon.ag
Internet: www.paragon.ag
ISIN: DE0005558696, DE000A2GSB86,
WKN: 555869, A2GSB8,
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
End of News DGAP News Service Reported by EQS Group 4 hours ago.
↧
Texas Board of Education considers eliminating Hillary Clinton, Helen Keller from curriculum
The Texas State board of Education on Tuesday will vote whether to eliminate major historical figures like Hillary Clinton and Helen Keller from the state’s social studies curriculum, The Austin American-Statesman reported.
Reported by FOXNews.com 4 hours ago.
↧
↧
Hunter setting up illegal deer blind shot approaching deputy: Texas cops
A Texas man, who set up an illegal deer blind, fired at a sheriff’s deputy as he approached him on Monday, officials said.
Reported by FOXNews.com 4 hours ago.
↧
Texas State steps into future of engineering education with $120M Ingram Hall
Texas State University last week christened the largest academic building in its history. Bruce and Gloria Ingram Hall, a new hub for the university's science and engineering programs that clocks in at more than 166,000 square feet, was feted with a ribbon-cutting ceremony Nov. 8. The $120 million building was paid for through donations by Bruce and Gloria Ingram, longtime Texas State backers, as well as a matching gift through the Texas Research Incentive Program It's part of a construction boom…
Reported by bizjournals 2 hours ago.
↧
M3-Wake Research Partners with EmergeOrtho to Create M3-Emerging Medical Research
New Clinical Research Site Expands Scope of Studies and Musculoskeletal Health Opportunities for Larger Patient Communities
RALEIGH, N.C. (PRWEB) November 13, 2018
M3 Wake Research Associates, among the nation’s largest Phase I-IV clinical trial site service companies in North America, announces a new partnership with EmergeOrtho, one of the largest physician-owned orthopedic practices in North Carolina, and a leading provider of innovative, quality, comprehensive musculoskeletal care. This new joint venture will form M3-Emerging Medical Research, expanding Wake Research’s coast-to-coast coverage of clinical research populations in the United States and incorporating communities of nearly 20 million people.
“Clinical research like this allows patients to have access to new treatments that may be otherwise unavailable, and advances the care of all patients,” stated David Musante, M.D., spine surgeon at EmergeOrtho. “EmergeOrtho and Wake Research both have an established, successful track record of performing cutting-edge clinical research. Combining forces as M3-Emerging Medical Research will enable us to provide even greater opportunities for our patients’ health.”
M3-Wake Research was originally founded by a large multi-specialty group practice and has conducted clinical research studies since 1984. Based in the Research Triangle Park area of Raleigh, NC, Wake Research has built a combined database of more than 950,000 subjects to date, within an integrated network of 15 research sites operating in seven states: Alabama, Arizona, California, Georgia, North Carolina, Tennessee, and Texas. Their board-certified physicians have completed more than 6,000 successful clinical trials in most major therapeutic areas, with particular expertise in gastroenterology, neuroscience, dermatology, endocrinology, immunology, and women’s health.
EmergeOrtho’s team includes more than 100 orthopedic specialty physicians serving patients from 49 locations and across 21 counties in North Carolina. Emerging Medical Research will be integrated as part of M3-Wake Research’s network, and will benefit from M3 Wake’s industry-leading infrastructure including centralized patient recruitment and retention, company-wide QA/QC program, an in-house training program, and marketing and advertising services.
“This exciting partnership brings one of the largest and most established, highly successful physician-owned orthopedic practices in the region into our nationwide research network,” stated Ella Grach, MD, President and Chief Executive Officer of Wake Research. “The EmergeOrtho team has built a strong operation offering an advanced expertise in all subspecialties related to conditions of the bones, muscles, and joints. With its reputation for being patient-focused, and as the ‘go-to practice’ for orthopedic care and research, EmergeOrtho will be a key part of our continued research network expansion,” Dr. Grach continued. “Together, we will continue meeting the evolving needs of the drug discovery process and closing the gap between clinical research and healthcare by offering clinical trials as a care option.”
As a result of this joint venture, Emerging Medical Research joins the family of M3 USA brands including MDLinx, a clinical education and medical news website, The Medicus Firm, a physician and advanced practitioner recruiting firm, and PracticeMatch, which provides healthcare employers with the nation’s largest physician recruitment marketing resource. No further financial details of the transaction were made publicly available at this time.
About M3 Inc.:
M3 Inc. operates in the US, Asia, and Europe with over 4 million physician members globally via its physician websites such as mdlinx.com, m3.com, research.m3.com, doctors.net.uk, medigate.net and medlive.cn. M3 Inc. is a publicly traded company on the Tokyo Stock Exchange (TYO:2413) with subsidiaries in major markets including USA, UK, Japan, S. Korea, and China. M3 Inc. provides services to healthcare and the life science industry. In addition to market research, these services include medical education, ethical drug promotion, clinical development, job recruitment, and clinic appointment services. M3 has offices in Tokyo, Washington D.C., Fort Washington, PA, Oxford, London, Beijing, and Seoul.
About M3-Wake Research, Inc.:
M3-Wake Research is an organization of integrated investigational sites, committed to excellence, working closely with and meeting the needs of the biopharmaceutical, biotechnology, medical device and pharmaceutical industries. M3-Wake Research’s 15 sites are fully equipped to meet the needs of sponsors and CROs in the conduct of Phase I-IV clinical trials in a large variety of indications.
M3-Wake Research is known for effectively combining strategic volunteer recruitment, rapid trial start-up and subject enrollment/retention with high quality clinical trial conduct, using standardized operating procedures and centralized marketing and advertising to ensure rapid subject enrollment. M3-Wake Research sites have conducted more than 6,000 research studies for hundreds of pharmaceutical and biotech sponsors and CROs. Wake Research’s mission is to bring novel medications, biologics and device through clinical research to as many people as possible while providing unparalleled service and exceptional value to clinical trial partners and stakeholders. Media contact: Cameron Knowles, Director of Advertising & Marketing – cknowles(at)wakeresearch(dot)com. 919.781.2514
About Emerge Ortho: In 2016, four of the state’s top orthopedic practices teamed up to provide the highest level of patient-centered care, delivered in a convenient, efficient and cost-effective manner. Now serving patients with 49 offices in 21 counties from the mountains to the coast, EmergeOrtho is one of the largest physician-owned orthopedic practices in North Carolina.
Statewide, EmergeOrtho’s medical team includes well over 100 highly trained orthopedic specialty physicians and nearly as many mid-level providers. This unparalleled team offers advanced expertise in all subspecialties dealing with conditions of the bones, muscles and joints, as well as unmatched resources through collaboration with other specialists in the practice. Reported by PRWeb 3 hours ago.
RALEIGH, N.C. (PRWEB) November 13, 2018
M3 Wake Research Associates, among the nation’s largest Phase I-IV clinical trial site service companies in North America, announces a new partnership with EmergeOrtho, one of the largest physician-owned orthopedic practices in North Carolina, and a leading provider of innovative, quality, comprehensive musculoskeletal care. This new joint venture will form M3-Emerging Medical Research, expanding Wake Research’s coast-to-coast coverage of clinical research populations in the United States and incorporating communities of nearly 20 million people.
“Clinical research like this allows patients to have access to new treatments that may be otherwise unavailable, and advances the care of all patients,” stated David Musante, M.D., spine surgeon at EmergeOrtho. “EmergeOrtho and Wake Research both have an established, successful track record of performing cutting-edge clinical research. Combining forces as M3-Emerging Medical Research will enable us to provide even greater opportunities for our patients’ health.”
M3-Wake Research was originally founded by a large multi-specialty group practice and has conducted clinical research studies since 1984. Based in the Research Triangle Park area of Raleigh, NC, Wake Research has built a combined database of more than 950,000 subjects to date, within an integrated network of 15 research sites operating in seven states: Alabama, Arizona, California, Georgia, North Carolina, Tennessee, and Texas. Their board-certified physicians have completed more than 6,000 successful clinical trials in most major therapeutic areas, with particular expertise in gastroenterology, neuroscience, dermatology, endocrinology, immunology, and women’s health.
EmergeOrtho’s team includes more than 100 orthopedic specialty physicians serving patients from 49 locations and across 21 counties in North Carolina. Emerging Medical Research will be integrated as part of M3-Wake Research’s network, and will benefit from M3 Wake’s industry-leading infrastructure including centralized patient recruitment and retention, company-wide QA/QC program, an in-house training program, and marketing and advertising services.
“This exciting partnership brings one of the largest and most established, highly successful physician-owned orthopedic practices in the region into our nationwide research network,” stated Ella Grach, MD, President and Chief Executive Officer of Wake Research. “The EmergeOrtho team has built a strong operation offering an advanced expertise in all subspecialties related to conditions of the bones, muscles, and joints. With its reputation for being patient-focused, and as the ‘go-to practice’ for orthopedic care and research, EmergeOrtho will be a key part of our continued research network expansion,” Dr. Grach continued. “Together, we will continue meeting the evolving needs of the drug discovery process and closing the gap between clinical research and healthcare by offering clinical trials as a care option.”
As a result of this joint venture, Emerging Medical Research joins the family of M3 USA brands including MDLinx, a clinical education and medical news website, The Medicus Firm, a physician and advanced practitioner recruiting firm, and PracticeMatch, which provides healthcare employers with the nation’s largest physician recruitment marketing resource. No further financial details of the transaction were made publicly available at this time.
About M3 Inc.:
M3 Inc. operates in the US, Asia, and Europe with over 4 million physician members globally via its physician websites such as mdlinx.com, m3.com, research.m3.com, doctors.net.uk, medigate.net and medlive.cn. M3 Inc. is a publicly traded company on the Tokyo Stock Exchange (TYO:2413) with subsidiaries in major markets including USA, UK, Japan, S. Korea, and China. M3 Inc. provides services to healthcare and the life science industry. In addition to market research, these services include medical education, ethical drug promotion, clinical development, job recruitment, and clinic appointment services. M3 has offices in Tokyo, Washington D.C., Fort Washington, PA, Oxford, London, Beijing, and Seoul.
About M3-Wake Research, Inc.:
M3-Wake Research is an organization of integrated investigational sites, committed to excellence, working closely with and meeting the needs of the biopharmaceutical, biotechnology, medical device and pharmaceutical industries. M3-Wake Research’s 15 sites are fully equipped to meet the needs of sponsors and CROs in the conduct of Phase I-IV clinical trials in a large variety of indications.
M3-Wake Research is known for effectively combining strategic volunteer recruitment, rapid trial start-up and subject enrollment/retention with high quality clinical trial conduct, using standardized operating procedures and centralized marketing and advertising to ensure rapid subject enrollment. M3-Wake Research sites have conducted more than 6,000 research studies for hundreds of pharmaceutical and biotech sponsors and CROs. Wake Research’s mission is to bring novel medications, biologics and device through clinical research to as many people as possible while providing unparalleled service and exceptional value to clinical trial partners and stakeholders. Media contact: Cameron Knowles, Director of Advertising & Marketing – cknowles(at)wakeresearch(dot)com. 919.781.2514
About Emerge Ortho: In 2016, four of the state’s top orthopedic practices teamed up to provide the highest level of patient-centered care, delivered in a convenient, efficient and cost-effective manner. Now serving patients with 49 offices in 21 counties from the mountains to the coast, EmergeOrtho is one of the largest physician-owned orthopedic practices in North Carolina.
Statewide, EmergeOrtho’s medical team includes well over 100 highly trained orthopedic specialty physicians and nearly as many mid-level providers. This unparalleled team offers advanced expertise in all subspecialties dealing with conditions of the bones, muscles and joints, as well as unmatched resources through collaboration with other specialists in the practice. Reported by PRWeb 3 hours ago.
↧
HR Is the New Marketing: Magnificent Marketing Presents a New Podcast Episode on the Modern Field of Marketing and the importance of Tapping into Employees’ Talents
If employees are happy and engaged, it will carry over into marketing, meaning it's more important than ever to foster a healthy work environment for business success. In a new podcast episode, marketing expert and author Michael Brenner - CEO of Marketing Inside Group - discusses how human resources are the foundation for modern marketing.
AUSTIN, Texas (PRWEB) November 13, 2018
In the latest episode of the Magnificent Marketing Podcast, Magnificent CEO sits down with Michael Brenner - CEO of Marketing Insider Group and the co-author of the best-selling book, “The Content Formula" - to present a podcast on HR as the new marketing.
In 2017, Brenner was listed by Forbes as a top CMO influencer and social media marketer. In this interview, Brenner discusses a range of topics surrounding the modern marketing field, particularly his concept that HR is the new marketing and the importance of tapping into employees’ talents.
As Brenner explains, if employees are happy and engaged then this will carry over into the marketing, and one of the most essential tenants of marketing is a human connection. If consumers sense that marketers are warm and inviting, as opposed to cold and distant, they end up being far more receptive.
This is tantamount in modern marketing because, as Brenner says, the game is no longer about pushing out ads, but, rather, to activate passion and expertise in the marketers.
He also dives into the following topics:
-The importance of brand trust
-Fostering a healthy work environment
-Incorporating employees into marketing efforts
-Overseeing employees' content (and when to do it)
-Convincing employees to engage and contribute
-The most common content creation mistakes
-And more!
This episode is available on main podcast channels, on Magnificent's YouTube channel and, along with an accompanying blog, on magnificent.com.
About Magnificent Marketing:
Magnificent Marketing is your full-service content marketing agency that will take care of all your marketing needs so that you can concentrate on the core duties needed to manage and grow your business.
Their objective is to generate leads that turn into customers while focusing on expanding the visibility of your company and brand, and positioning you to be "top of mind" for future potential clients.
In order to achieve this, they draw on their experience and belief that a mixture of traditional marketing techniques combined with modern marketing tools will yield the best results. In other words, they blend old and new school marketing to create the best school of thought.
About Michael Brenner:
Michael Brenner is a globally-recognized keynote speaker, author of The Content Formula and the CEO of Marketing Insider Group. He has worked in leadership positions in sales and marketing for global brands like SAP and Nielsen, as well as for thriving startups. Today, Michael shares his passion on leadership and marketing strategies that deliver customer value and business impact. He is recognized by the Huffington Post as a Top Business Keynote Speaker and a top CMO influencer by Forbes. Follow Michael on Twitter @BrennerMichael. Reported by PRWeb 3 hours ago.
AUSTIN, Texas (PRWEB) November 13, 2018
In the latest episode of the Magnificent Marketing Podcast, Magnificent CEO sits down with Michael Brenner - CEO of Marketing Insider Group and the co-author of the best-selling book, “The Content Formula" - to present a podcast on HR as the new marketing.
In 2017, Brenner was listed by Forbes as a top CMO influencer and social media marketer. In this interview, Brenner discusses a range of topics surrounding the modern marketing field, particularly his concept that HR is the new marketing and the importance of tapping into employees’ talents.
As Brenner explains, if employees are happy and engaged then this will carry over into the marketing, and one of the most essential tenants of marketing is a human connection. If consumers sense that marketers are warm and inviting, as opposed to cold and distant, they end up being far more receptive.
This is tantamount in modern marketing because, as Brenner says, the game is no longer about pushing out ads, but, rather, to activate passion and expertise in the marketers.
He also dives into the following topics:
-The importance of brand trust
-Fostering a healthy work environment
-Incorporating employees into marketing efforts
-Overseeing employees' content (and when to do it)
-Convincing employees to engage and contribute
-The most common content creation mistakes
-And more!
This episode is available on main podcast channels, on Magnificent's YouTube channel and, along with an accompanying blog, on magnificent.com.
About Magnificent Marketing:
Magnificent Marketing is your full-service content marketing agency that will take care of all your marketing needs so that you can concentrate on the core duties needed to manage and grow your business.
Their objective is to generate leads that turn into customers while focusing on expanding the visibility of your company and brand, and positioning you to be "top of mind" for future potential clients.
In order to achieve this, they draw on their experience and belief that a mixture of traditional marketing techniques combined with modern marketing tools will yield the best results. In other words, they blend old and new school marketing to create the best school of thought.
About Michael Brenner:
Michael Brenner is a globally-recognized keynote speaker, author of The Content Formula and the CEO of Marketing Insider Group. He has worked in leadership positions in sales and marketing for global brands like SAP and Nielsen, as well as for thriving startups. Today, Michael shares his passion on leadership and marketing strategies that deliver customer value and business impact. He is recognized by the Huffington Post as a Top Business Keynote Speaker and a top CMO influencer by Forbes. Follow Michael on Twitter @BrennerMichael. Reported by PRWeb 3 hours ago.
↧
↧
Aladtec Representatives Attending Texas EMS Conference
Five-day event at Fort Worth Convention Center expected to draw 3,200-plus
FORT WORTH, Texas (PRWEB) November 13, 2018
Emergency medical service professionals from across Texas will gather at the Fort Worth Convention Center next week to learn, trade ideas and visit with about 150 vendors -- including Aladtec, a premier provider of cloud-based scheduling and workforce management software for public safety.
Representatives Joe Ellis and Jake Tormoen from Aladtec, Inc., will be part of the two-day exhibition, meeting with existing customers and demonstrating Aladtec's unique scheduling, form-building, and communications tools to EMS leaders.
Ellis and Tormoen will offer demonstrations at Booth #657 during the conference. Expo hours are 1-7 pm, Sunday, Nov. 18, and 9:10 am to 1 pm, Saturday.
Aladtec's robust platform is designed to accommodate the non-traditional scheduling and workplace activities associated with public safety agencies. Aladtec software is used by 39 Texas EMS agencies and 44 more fire, law enforcement, dispatch centers, and healthcare organizations in the Lone Star State.
Most EMS agencies need to manage 24/7 shift rotations for both full-time and part-time employees. Communication tools embedded in the Aladtec platform enable staff to initiate swaps and trades, request time-off and receive schedule reminders while allowing administrators to make approvals and fill open shifts in minutes. Users access the secure system via any smartphone, tablet, or desktop computer connected to the internet.
“Prior to using Aladtec, I spent a lot of time dealing with trade requests from members. Now they take care of their own trades. It's also very easy to check the schedule from anywhere,” said Dale Dow, deputy chief with Fitch Rona Fire & EMS, which serves the Dane County (WI) communities of Fitchburg and Verona. “We'll never go back to paper scheduling."
Other Aladtec features allow for easy tracking of certifications and licenses, creation and management of electronic forms, a member discussion forum, abundant storage for policies and procedures, and much more. Many customers say they pay for the low-cost annual subscription through time savings in just weeks or a couple of months.
The platform improves agency efficiency, reduces human error, and streamlines processes. After implementing Aladtec, agencies also report reduced overtime and reducing staff time spent on employee scheduling and management chores.
View a short video about how Aladtec has streamlined tasks at Great Falls (MT) Emergency Medical Services.
The three-day agenda at the Fort Worth conference includes dozens of workshops and lectures, plus award ceremonies and fellowship activities aimed at driving professional development.
One presentation by a nationally-recognized attorney -- himself a former paramedic, fire officer, and EMS executive -- is entitled "The 7 Biggest Threats to Your EMS Agency". The presenters, Steve Wirth, and associate Doug Wolfberg, promise a thought-provoking capsule version of the challenges, threats, and opportunities that await EMS organizations amid today's changing social, cultural and regulatory environment.
Other session titles include: Patient and Provider Safety in EMS: We all have room to improve; Breaking Bad News; Hands-on Orthopedic Assessment; Bleeding Control from the Inside Out; When Patients Say No: Liability with Patient Refusals; Slavery Today? Human Trafficking: What can EMS Do?, and many more.
To learn more about Aladtec now, visit http://www.aladtec.com, or call 888-749-5550 and a representative will be pleased to answer any questions or configure a 14-day free trial, customized to an agency's unique operating practices.
CONTACT INFORMATION:
Aladtec, Inc.
387 Arrow Court
River Falls, WI 54022
(888) 749-5550 Toll-Free
(715) 690-2300 Phone
steve@aladtec.com
http://www.aladtec.com Reported by PRWeb 3 hours ago.
FORT WORTH, Texas (PRWEB) November 13, 2018
Emergency medical service professionals from across Texas will gather at the Fort Worth Convention Center next week to learn, trade ideas and visit with about 150 vendors -- including Aladtec, a premier provider of cloud-based scheduling and workforce management software for public safety.
Representatives Joe Ellis and Jake Tormoen from Aladtec, Inc., will be part of the two-day exhibition, meeting with existing customers and demonstrating Aladtec's unique scheduling, form-building, and communications tools to EMS leaders.
Ellis and Tormoen will offer demonstrations at Booth #657 during the conference. Expo hours are 1-7 pm, Sunday, Nov. 18, and 9:10 am to 1 pm, Saturday.
Aladtec's robust platform is designed to accommodate the non-traditional scheduling and workplace activities associated with public safety agencies. Aladtec software is used by 39 Texas EMS agencies and 44 more fire, law enforcement, dispatch centers, and healthcare organizations in the Lone Star State.
Most EMS agencies need to manage 24/7 shift rotations for both full-time and part-time employees. Communication tools embedded in the Aladtec platform enable staff to initiate swaps and trades, request time-off and receive schedule reminders while allowing administrators to make approvals and fill open shifts in minutes. Users access the secure system via any smartphone, tablet, or desktop computer connected to the internet.
“Prior to using Aladtec, I spent a lot of time dealing with trade requests from members. Now they take care of their own trades. It's also very easy to check the schedule from anywhere,” said Dale Dow, deputy chief with Fitch Rona Fire & EMS, which serves the Dane County (WI) communities of Fitchburg and Verona. “We'll never go back to paper scheduling."
Other Aladtec features allow for easy tracking of certifications and licenses, creation and management of electronic forms, a member discussion forum, abundant storage for policies and procedures, and much more. Many customers say they pay for the low-cost annual subscription through time savings in just weeks or a couple of months.
The platform improves agency efficiency, reduces human error, and streamlines processes. After implementing Aladtec, agencies also report reduced overtime and reducing staff time spent on employee scheduling and management chores.
View a short video about how Aladtec has streamlined tasks at Great Falls (MT) Emergency Medical Services.
The three-day agenda at the Fort Worth conference includes dozens of workshops and lectures, plus award ceremonies and fellowship activities aimed at driving professional development.
One presentation by a nationally-recognized attorney -- himself a former paramedic, fire officer, and EMS executive -- is entitled "The 7 Biggest Threats to Your EMS Agency". The presenters, Steve Wirth, and associate Doug Wolfberg, promise a thought-provoking capsule version of the challenges, threats, and opportunities that await EMS organizations amid today's changing social, cultural and regulatory environment.
Other session titles include: Patient and Provider Safety in EMS: We all have room to improve; Breaking Bad News; Hands-on Orthopedic Assessment; Bleeding Control from the Inside Out; When Patients Say No: Liability with Patient Refusals; Slavery Today? Human Trafficking: What can EMS Do?, and many more.
To learn more about Aladtec now, visit http://www.aladtec.com, or call 888-749-5550 and a representative will be pleased to answer any questions or configure a 14-day free trial, customized to an agency's unique operating practices.
CONTACT INFORMATION:
Aladtec, Inc.
387 Arrow Court
River Falls, WI 54022
(888) 749-5550 Toll-Free
(715) 690-2300 Phone
steve@aladtec.com
http://www.aladtec.com Reported by PRWeb 3 hours ago.
↧
Lightning Labels Exhibiting at the Imperious Expo Ark-La-Tex in Little Rock, AK December 12-13
Meet with our label experts and learn how to maximize your brand and drive cannabis sales!
DENVER (PRWEB) November 13, 2018
Working within the medical and recreational cannabis industries presents exciting possibilities and opportunities for entrepreneurs. The Imperious Expo Ark-La-Tex offers companies in these sectors a chance to connect, share information and build partnerships. Lightning Labels is among the companies exhibiting at this show, with representatives on hand to show the potential impact of custom cannabis labels.
Exploring the Cannabis Expo Ark-La-Tex
The business-to-business communication at industry shows is helpful for organizations in the medical marijuana industry, and the Ark-La-Tex Expo 2018 is designed to facilitate these meetings. From Dec. 12-13, dozens of companies, government agencies and other organizations will send representatives to Little Rock for the convention. Keynote speeches and presentations will provide valuable insider perspectives on the present and future of cannabis business.
"Industry gatherings provide an ideal chance for cannabis entrepreneurs to meet and learn best practices," said Lightning Labels Director of Sales and Client Services Gary Paulin. "We're thrilled to have this chance to demonstrate the importance of good custom labeling to Arkansas, Louisiana and Texas business people."
Learning the Value of Cannabis Labels
When the legal marijuana industry first commenced over a decade ago, labeling best practices simply meant complying with relevant laws. Now, to stand out among increasing competition, companies must also master design and branding. The Lightning Labels Booth at the Imperious Expo Ark-La-Tex is a great place to see custom labeling in action.
About Lightning Labels:
Lightning Labels uses state-of-the-art printing technology to provide affordable, full-color custom labels and custom stickers of all shapes and sizes. From small orders for individuals to the bulk needs of big businesses, Lightning Labels is equipped to handle and fulfill custom label and sticker projects of all types. Best of all, like the name implies, Lightning Labels provides a quick turnaround for every customer's labeling needs. Uses for Lightning Labels' custom product labels and custom stickers include food packaging and organic food labels, wine and beverage labels, bath and body labels, and nutraceutical products, such as vitamins, essentials oils, and herbal remedies, as well as event stickers, adhesive window stickers and more. Lightning Labels strongly supports the development of environmentally friendly printing materials and carries EarthFirst PLA, a new kind of green label material made from corn instead of petroleum. While operating as a high-tech printer, Lightning Labels prides itself on its personalized customer service. Lightning Labels provides one stop shopping for all of your custom label needs. For more information and to place orders online, visit LightningLabels.com. For the latest in packaging news and labeling promotional offers, find Lightning Labels on Twitter (@LightningLabels), Facebook, Pinterest, Google+ and LinkedIn. Reported by PRWeb 3 hours ago.
DENVER (PRWEB) November 13, 2018
Working within the medical and recreational cannabis industries presents exciting possibilities and opportunities for entrepreneurs. The Imperious Expo Ark-La-Tex offers companies in these sectors a chance to connect, share information and build partnerships. Lightning Labels is among the companies exhibiting at this show, with representatives on hand to show the potential impact of custom cannabis labels.
Exploring the Cannabis Expo Ark-La-Tex
The business-to-business communication at industry shows is helpful for organizations in the medical marijuana industry, and the Ark-La-Tex Expo 2018 is designed to facilitate these meetings. From Dec. 12-13, dozens of companies, government agencies and other organizations will send representatives to Little Rock for the convention. Keynote speeches and presentations will provide valuable insider perspectives on the present and future of cannabis business.
"Industry gatherings provide an ideal chance for cannabis entrepreneurs to meet and learn best practices," said Lightning Labels Director of Sales and Client Services Gary Paulin. "We're thrilled to have this chance to demonstrate the importance of good custom labeling to Arkansas, Louisiana and Texas business people."
Learning the Value of Cannabis Labels
When the legal marijuana industry first commenced over a decade ago, labeling best practices simply meant complying with relevant laws. Now, to stand out among increasing competition, companies must also master design and branding. The Lightning Labels Booth at the Imperious Expo Ark-La-Tex is a great place to see custom labeling in action.
About Lightning Labels:
Lightning Labels uses state-of-the-art printing technology to provide affordable, full-color custom labels and custom stickers of all shapes and sizes. From small orders for individuals to the bulk needs of big businesses, Lightning Labels is equipped to handle and fulfill custom label and sticker projects of all types. Best of all, like the name implies, Lightning Labels provides a quick turnaround for every customer's labeling needs. Uses for Lightning Labels' custom product labels and custom stickers include food packaging and organic food labels, wine and beverage labels, bath and body labels, and nutraceutical products, such as vitamins, essentials oils, and herbal remedies, as well as event stickers, adhesive window stickers and more. Lightning Labels strongly supports the development of environmentally friendly printing materials and carries EarthFirst PLA, a new kind of green label material made from corn instead of petroleum. While operating as a high-tech printer, Lightning Labels prides itself on its personalized customer service. Lightning Labels provides one stop shopping for all of your custom label needs. For more information and to place orders online, visit LightningLabels.com. For the latest in packaging news and labeling promotional offers, find Lightning Labels on Twitter (@LightningLabels), Facebook, Pinterest, Google+ and LinkedIn. Reported by PRWeb 3 hours ago.
↧
Imagination reveals next step in PowerVR automotive strategy
*15-year automotive veteran’s product package to accelerate growing market*
LONDON and TOKYO, Nov. 13, 2018 (GLOBE NEWSWIRE) -- Imagination Technologies announces PowerVR Automotive, a complete product package to enable growth and acceleration of the automotive semiconductor industry. Combining five essential elements – hardware IP, software, tools, documentation and long-term support – PowerVR Automotive enables existing customers and new entrants in the market to meet the safety standards and performance requirements of the industry as it moves towards fully autonomous driving.
Imagination is introducing the PowerVR Series8XT-A GPU core to complement its existing IP already used extensively in infotainment, digital cockpit and advanced driver assistance systems (ADAS). PowerVR Series8XT-A has enhanced recovery and reliability features to make it easier for System-on-Chip (SoC) designers to obtain automotive safety certification for their SoCs aimed at digital human-machine interfaces (HMIs) and autonomous vehicles (AVs).
*Why PowerVR Automotive?*
Automotive applications have specific requirements that impact all aspects of system design and which standard consumer IP is not able to meet. To solve this, PowerVR Automotive provides customers with a complete package of support documentation, automotive safety and traceability information that’s designed to ensure customers’ SoCs can achieve the ASIL-levels of functional safety, meeting industry standards such as ISO 26262 and IEC 61506 at the system level. Based on Imagination’s extensive knowledge of the automotive market, the company offers proven long-term support (LTS) packages for ten years and beyond, to give customers confidence and assurance for the life-time of their products.
To ensure suitability for the demanding automotive market, the entire package was conceived, designed and tested under Imagination’s mature quality management processes, led by a dedicated and independent safety team.
PowerVR IP has been a key enabler for leading-edge automotive products since 2006. Its GPUs have been licensed by multiple leading automotive applications processor vendors, including DENSO, Renesas, Socionext, Texas Instruments (TI) and others. To date these companies have shipped tens-of-millions of devices, giving Imagination a market share by volume of over 50% for automotive application processors.
Leo Li, CEO, Imagination Technologies, says: “The automotive industry is rapidly transitioning to assisted driving and fully autonomous vehicles. PowerVR has extensive experience in the automotive semiconductor market and as the requirements for power and performance continue to evolve, PowerVR is committed to remaining ahead of the curve. Imagination is excited to deliver this package that allows the growing group of automotive players to address the complex requirements of this market.”
*Delivering the PowerVR Automotive package*
The PowerVR Automotive package reduces the barrier to entry for new players to the market, while easing the burden of meeting safety requirement for established companies.
The comprehensive automotive package extends the application of PowerVR’s quality-managed IP to automotive solutions. Customers have a wide choice of IP with access to the extended safety package to meet automotive industry certification. This comprises of hardware IP, software and tools, automotive operating systems and hypervisor support, documentation and analysis, and development traceability.
Dominique Bonte, vice president, vertical markets, ABI Research, says: “The speed of progress in automotive is finally approaching that of Imagination’s traditional markets, such as mobile. Imagination’s dedicated PowerVR Automotive suite will allow automotive semiconductor vendors to accelerate time to market in terms of supporting automotive requirements like functional safety, virtualization, and power optimization through a turnkey solution.”
*Introducing PowerVR Series8XT-A GPU*
Based on the PowerVR Furian architecture, the Series8XT-A is a new member of the Series8XT family of GPUs targeted at cluster, HUD, infotainment and the digital cockpit, as well as ADAS functions. The Series8XT-A provides class-leading power, performance and area (PPA) metrics and enables new features in hardware and software for fault detection and recovery of the GPU. Other new features include Error-Correcting Code (ECC), Logic Built-in Self-test (LBIST), as well as industry-leading verification strategies.
Featuring unique built-in hardware virtualization, Series8XT-A enables automotive OEMs to keep multiple applications and services running securely in isolated containers, with guaranteed quality of service (QoS) for each.
*PowerVR Neural Network Accelerators (NNA) for Automotive *
Neural networks are becoming a fundamental element in the development of automotive; from the occupant’s experience, through to ADAS and autonomous driving.
The multi award-winning PowerVR Series2NX NNA is showcased through ADAS applications such as driver monitoring, driver gaze tracking, seat occupancy, road-sign detection, drivable path analysis, road user detection and driver recognition. Thanks to its performance density for embedded environments, PowerVR’s NNA technology will play a key role in enabling the industry to move from Level 3 to Level 5 autonomous driving.
Imagination’s ability to combine leading-edge GPU and NNA technology provides the industry with significant flexibility for creating automotive solutions, while at the same time as reducing risk, by future-proofing for industry evolution over the life of a product.
*Availability*
PowerVR Series8XT-A GPU is available for licensing now. The next generation of PowerVR GPUs and NNAs for automotive will be available during 2019. For further information, please contact info@imgtec.com.
*About Imagination Technologies
*Imagination is a global technology leader whose products touch the lives of billions of people across the globe. The company’s broad range of silicon IP (intellectual property) includes the key processing blocks needed to create the SoCs (Systems on Chips) that power all mobile, consumer and embedded electronics. Its unique software IP, infrastructure technologies and system solutions enable its customers to get to market quickly with complete and highly differentiated SoC platforms. Imagination’s licensees include many of the world’s leading semiconductor manufacturers, network operators and OEMs/ODMs who are creating some of the world’s most iconic products. See: www.imgtec.com.
Follow Imagination on Twitter, YouTube, LinkedIn, RSS, Facebook and Blog.
Imagination, PowerVR and the Imagination Technologies logo are trademarks of Imagination Technologies Limited and/or its affiliated group companies in the United Kingdom and/or other countries.
Imagination Technologies was acquired in 2017 by Canyon Bridge, a California-headquartered, global private equity investment fund.
*Imagination Technologies’ Press Contacts:
*David Harold david.harold@imgtec.com +44 (0)1923 260 511
Jo Ashford jo.ashford@imgtec.com +44 (0)1923 260 511 Reported by GlobeNewswire 3 hours ago.
LONDON and TOKYO, Nov. 13, 2018 (GLOBE NEWSWIRE) -- Imagination Technologies announces PowerVR Automotive, a complete product package to enable growth and acceleration of the automotive semiconductor industry. Combining five essential elements – hardware IP, software, tools, documentation and long-term support – PowerVR Automotive enables existing customers and new entrants in the market to meet the safety standards and performance requirements of the industry as it moves towards fully autonomous driving.
Imagination is introducing the PowerVR Series8XT-A GPU core to complement its existing IP already used extensively in infotainment, digital cockpit and advanced driver assistance systems (ADAS). PowerVR Series8XT-A has enhanced recovery and reliability features to make it easier for System-on-Chip (SoC) designers to obtain automotive safety certification for their SoCs aimed at digital human-machine interfaces (HMIs) and autonomous vehicles (AVs).
*Why PowerVR Automotive?*
Automotive applications have specific requirements that impact all aspects of system design and which standard consumer IP is not able to meet. To solve this, PowerVR Automotive provides customers with a complete package of support documentation, automotive safety and traceability information that’s designed to ensure customers’ SoCs can achieve the ASIL-levels of functional safety, meeting industry standards such as ISO 26262 and IEC 61506 at the system level. Based on Imagination’s extensive knowledge of the automotive market, the company offers proven long-term support (LTS) packages for ten years and beyond, to give customers confidence and assurance for the life-time of their products.
To ensure suitability for the demanding automotive market, the entire package was conceived, designed and tested under Imagination’s mature quality management processes, led by a dedicated and independent safety team.
PowerVR IP has been a key enabler for leading-edge automotive products since 2006. Its GPUs have been licensed by multiple leading automotive applications processor vendors, including DENSO, Renesas, Socionext, Texas Instruments (TI) and others. To date these companies have shipped tens-of-millions of devices, giving Imagination a market share by volume of over 50% for automotive application processors.
Leo Li, CEO, Imagination Technologies, says: “The automotive industry is rapidly transitioning to assisted driving and fully autonomous vehicles. PowerVR has extensive experience in the automotive semiconductor market and as the requirements for power and performance continue to evolve, PowerVR is committed to remaining ahead of the curve. Imagination is excited to deliver this package that allows the growing group of automotive players to address the complex requirements of this market.”
*Delivering the PowerVR Automotive package*
The PowerVR Automotive package reduces the barrier to entry for new players to the market, while easing the burden of meeting safety requirement for established companies.
The comprehensive automotive package extends the application of PowerVR’s quality-managed IP to automotive solutions. Customers have a wide choice of IP with access to the extended safety package to meet automotive industry certification. This comprises of hardware IP, software and tools, automotive operating systems and hypervisor support, documentation and analysis, and development traceability.
Dominique Bonte, vice president, vertical markets, ABI Research, says: “The speed of progress in automotive is finally approaching that of Imagination’s traditional markets, such as mobile. Imagination’s dedicated PowerVR Automotive suite will allow automotive semiconductor vendors to accelerate time to market in terms of supporting automotive requirements like functional safety, virtualization, and power optimization through a turnkey solution.”
*Introducing PowerVR Series8XT-A GPU*
Based on the PowerVR Furian architecture, the Series8XT-A is a new member of the Series8XT family of GPUs targeted at cluster, HUD, infotainment and the digital cockpit, as well as ADAS functions. The Series8XT-A provides class-leading power, performance and area (PPA) metrics and enables new features in hardware and software for fault detection and recovery of the GPU. Other new features include Error-Correcting Code (ECC), Logic Built-in Self-test (LBIST), as well as industry-leading verification strategies.
Featuring unique built-in hardware virtualization, Series8XT-A enables automotive OEMs to keep multiple applications and services running securely in isolated containers, with guaranteed quality of service (QoS) for each.
*PowerVR Neural Network Accelerators (NNA) for Automotive *
Neural networks are becoming a fundamental element in the development of automotive; from the occupant’s experience, through to ADAS and autonomous driving.
The multi award-winning PowerVR Series2NX NNA is showcased through ADAS applications such as driver monitoring, driver gaze tracking, seat occupancy, road-sign detection, drivable path analysis, road user detection and driver recognition. Thanks to its performance density for embedded environments, PowerVR’s NNA technology will play a key role in enabling the industry to move from Level 3 to Level 5 autonomous driving.
Imagination’s ability to combine leading-edge GPU and NNA technology provides the industry with significant flexibility for creating automotive solutions, while at the same time as reducing risk, by future-proofing for industry evolution over the life of a product.
*Availability*
PowerVR Series8XT-A GPU is available for licensing now. The next generation of PowerVR GPUs and NNAs for automotive will be available during 2019. For further information, please contact info@imgtec.com.
*About Imagination Technologies
*Imagination is a global technology leader whose products touch the lives of billions of people across the globe. The company’s broad range of silicon IP (intellectual property) includes the key processing blocks needed to create the SoCs (Systems on Chips) that power all mobile, consumer and embedded electronics. Its unique software IP, infrastructure technologies and system solutions enable its customers to get to market quickly with complete and highly differentiated SoC platforms. Imagination’s licensees include many of the world’s leading semiconductor manufacturers, network operators and OEMs/ODMs who are creating some of the world’s most iconic products. See: www.imgtec.com.
Follow Imagination on Twitter, YouTube, LinkedIn, RSS, Facebook and Blog.
Imagination, PowerVR and the Imagination Technologies logo are trademarks of Imagination Technologies Limited and/or its affiliated group companies in the United Kingdom and/or other countries.
Imagination Technologies was acquired in 2017 by Canyon Bridge, a California-headquartered, global private equity investment fund.
*Imagination Technologies’ Press Contacts:
*David Harold david.harold@imgtec.com +44 (0)1923 260 511
Jo Ashford jo.ashford@imgtec.com +44 (0)1923 260 511 Reported by GlobeNewswire 3 hours ago.
↧
Goods going through Texas gulf increase 24 percent
Goods and commodities going through the Houston-Galveston Customs District totaled more than $172.7 billion through the first nine months of 2018. That represents a 24 percent increase from $139.3 billion for the same time frame a year ago, according to foreign trade data from the Greater Houston Partnership. The Houston-Galveston Customs District is the seventh-busiest U.S. Customs district by dollar value in the country, but ranks first in the nation in terms of tonnage handled, per the report.…
Reported by bizjournals 2 hours ago.
↧
↧
Dell Children’s Medical Center of Central Texas Gets Austin Area Students Moving and Learning with GoNoodle®
Dell Children's Medical Center of Central Texas is funding GoNoodle for use in 133 Austin ISD, Round Rock ISD, and Hays ISD elementary schools as part of its effort to transform the health of kids and families in the Austin area.
AUSTIN, Texas (PRWEB) November 13, 2018
Dell Children’s Medical Center of Central Texas has partnered with GoNoodle to get over 78,000 kids in Austin area elementary schools moving more at school and at home. According to the CDC, only one-quarter of today’s youth meet the current recommendation of at least 60 minutes of physical activity per day. GoNoodle’s movement and mindfulness videos get kids up and moving with purpose in the classroom and at home - turning screen time into active time. Research has shown that participating in activities like GoNoodle not only improves physical health, but also improves academic performance and decreases behavior issues. Additionally, moving together with classmates creates community in the classroom which creates a positive environment for learning.
Dell Children’s Medical Center of Central Texas is fully funding the cost of GoNoodle's premium version, GoNoodle Plus, for three years for all 133 public elementary schools in Austin ISD, Round Rock ISD, and Hays ISD. The goal of the partnership is to increase physical activity among kids by providing access to GoNoodle’s hundreds of movement and mindfulness videos. Teachers will also have access to GoNoodle Plus which includes additional games and learning extensions that bring movement and core-subjects together to develop fluency in grade-specific math and ELA topics. With GoNoodle Plus, Austin-area elementary teachers have the ability to customize GoNoodle content, which further supports their lesson plans and academic goals of the classroom.
“Dell Children’s is proud to support Austin ISD, Round Rock ISD, and Hays ISD in promoting healthy lifestyles for every child,” said Craig Cordola, President and CEO Ascension Texas. “Through GoNoodle, Dell Children’s is providing teachers and students in over 133 of our local elementary schools access to an interactive tool encouraging physical activity and brain breaks which are research-based strategies for improving academic achievement.”
Together with Dell Children’s Medical Center of Central Texas, GoNoodle is helping local students get vital minutes of physical activity with entertaining experiences that feature high-energy dance music, fitness routines, virtual field trips and physical challenges. Over 14 million kids play GoNoodle each month, generating over six billion minutes of movement in the past year alone.
“Our partnership with Dell Children’s Medical Center of Central Texas is a powerful example of how local communities can invest in their future by putting kids first,” said KC Estenson, CEO of GoNoodle. “Teachers and students need all the resources they can get and we’re proud that GoNoodle can help them reach their goals both in the classroom and at home.”
To use GoNoodle, teachers need a computer with an internet connection and a shared screen such as a projector or interactive whiteboard. Kids can access the same GoNoodle content at home online, on ios or Android devices and through Apple TV. Teachers, parents and kids can sign up for a free account at gonoodle.com. Courtesy of Dell Children’s, public elementary school teachers, parents and kids in the three district coverage areas will have free access to GoNoodle Plus when they sign up.
About Ascension Texas
In Texas, Ascension operates Providence Healthcare Network and Seton Healthcare Family, which includes Dell Children’s Medical Center of Central Texas, the region’s only comprehensive children’s hospital and pediatric Level I trauma center, and Dell Seton Medical Center at The University of Texas, the region’s only Level I trauma center for adults. Seton partners with Dell Medical School at The University of Texas at Austin, and shares a common vision of transforming healthcare through a focus on quality and value. Serving Texas for 115 years, Ascension is a faith-based healthcare organization committed to delivering compassionate, personalized care to all, with special attention to persons living in poverty and those most vulnerable. Ascension is the largest non-profit health system in the U.S. and the world’s largest Catholic health system, operating more than 2,600 sites of care – including 151 hospitals and more than 50 senior living facilities in 22 states and the District of Columbia. Visit http://www.dellchildrens.net, http://www.providence.net and http://www.seton.net.
About GoNoodle
GoNoodle gets kids moving to be their smartest, strongest, bravest, silliest, bestest selves. GoNoodle’s 100s of short interactive videos and games get kids moving throughout the day, keeping them energized and focused, while introducing curricular topics, practicing mindfulness or just getting the wiggles out. It is one of the fastest adopted tech resources and is proven to deliver measurable gains in academic performance and student health. Over 14 million kids move to GoNoodle each month. It is used in 4 out of 5 U.S. public elementary schools in all 50 states and worldwide in 185 countries. 2 million families play GoNoodle at home, turning screen time into active time, through gonoodle.com, apps for iPhone, Android and Apple TV and through the GoNoodle YouTube channel. Learn more at http://www.gonoodle.com. Reported by PRWeb 2 hours ago.
AUSTIN, Texas (PRWEB) November 13, 2018
Dell Children’s Medical Center of Central Texas has partnered with GoNoodle to get over 78,000 kids in Austin area elementary schools moving more at school and at home. According to the CDC, only one-quarter of today’s youth meet the current recommendation of at least 60 minutes of physical activity per day. GoNoodle’s movement and mindfulness videos get kids up and moving with purpose in the classroom and at home - turning screen time into active time. Research has shown that participating in activities like GoNoodle not only improves physical health, but also improves academic performance and decreases behavior issues. Additionally, moving together with classmates creates community in the classroom which creates a positive environment for learning.
Dell Children’s Medical Center of Central Texas is fully funding the cost of GoNoodle's premium version, GoNoodle Plus, for three years for all 133 public elementary schools in Austin ISD, Round Rock ISD, and Hays ISD. The goal of the partnership is to increase physical activity among kids by providing access to GoNoodle’s hundreds of movement and mindfulness videos. Teachers will also have access to GoNoodle Plus which includes additional games and learning extensions that bring movement and core-subjects together to develop fluency in grade-specific math and ELA topics. With GoNoodle Plus, Austin-area elementary teachers have the ability to customize GoNoodle content, which further supports their lesson plans and academic goals of the classroom.
“Dell Children’s is proud to support Austin ISD, Round Rock ISD, and Hays ISD in promoting healthy lifestyles for every child,” said Craig Cordola, President and CEO Ascension Texas. “Through GoNoodle, Dell Children’s is providing teachers and students in over 133 of our local elementary schools access to an interactive tool encouraging physical activity and brain breaks which are research-based strategies for improving academic achievement.”
Together with Dell Children’s Medical Center of Central Texas, GoNoodle is helping local students get vital minutes of physical activity with entertaining experiences that feature high-energy dance music, fitness routines, virtual field trips and physical challenges. Over 14 million kids play GoNoodle each month, generating over six billion minutes of movement in the past year alone.
“Our partnership with Dell Children’s Medical Center of Central Texas is a powerful example of how local communities can invest in their future by putting kids first,” said KC Estenson, CEO of GoNoodle. “Teachers and students need all the resources they can get and we’re proud that GoNoodle can help them reach their goals both in the classroom and at home.”
To use GoNoodle, teachers need a computer with an internet connection and a shared screen such as a projector or interactive whiteboard. Kids can access the same GoNoodle content at home online, on ios or Android devices and through Apple TV. Teachers, parents and kids can sign up for a free account at gonoodle.com. Courtesy of Dell Children’s, public elementary school teachers, parents and kids in the three district coverage areas will have free access to GoNoodle Plus when they sign up.
About Ascension Texas
In Texas, Ascension operates Providence Healthcare Network and Seton Healthcare Family, which includes Dell Children’s Medical Center of Central Texas, the region’s only comprehensive children’s hospital and pediatric Level I trauma center, and Dell Seton Medical Center at The University of Texas, the region’s only Level I trauma center for adults. Seton partners with Dell Medical School at The University of Texas at Austin, and shares a common vision of transforming healthcare through a focus on quality and value. Serving Texas for 115 years, Ascension is a faith-based healthcare organization committed to delivering compassionate, personalized care to all, with special attention to persons living in poverty and those most vulnerable. Ascension is the largest non-profit health system in the U.S. and the world’s largest Catholic health system, operating more than 2,600 sites of care – including 151 hospitals and more than 50 senior living facilities in 22 states and the District of Columbia. Visit http://www.dellchildrens.net, http://www.providence.net and http://www.seton.net.
About GoNoodle
GoNoodle gets kids moving to be their smartest, strongest, bravest, silliest, bestest selves. GoNoodle’s 100s of short interactive videos and games get kids moving throughout the day, keeping them energized and focused, while introducing curricular topics, practicing mindfulness or just getting the wiggles out. It is one of the fastest adopted tech resources and is proven to deliver measurable gains in academic performance and student health. Over 14 million kids move to GoNoodle each month. It is used in 4 out of 5 U.S. public elementary schools in all 50 states and worldwide in 185 countries. 2 million families play GoNoodle at home, turning screen time into active time, through gonoodle.com, apps for iPhone, Android and Apple TV and through the GoNoodle YouTube channel. Learn more at http://www.gonoodle.com. Reported by PRWeb 2 hours ago.
↧
Bluecloud Africa Officially Established by Healthcarepoint to Support Smart City Development in the Continent
BlueCloud office will be headquartered in Nairobi, Kenya, to help local organizations modernize the African Healthcare and Clinical Research ecosystem using smart city approaches.
AUSTIN, Texas (PRWEB) November 13, 2018
BlueCloud by HealthCarePoint (HCP), a Texas-based healthcare and clinical research networking technology company founded by patient survivors, established BlueCloud Africa to work with local organizations to improve the healthcare and clinical research ecosystem using smart city development approaches. A “smart city” is commonly known as, “an area where information and communication technology, and various physical devices are connected to networks to optimize the efficiency of city operations and services and connect to citizens.” BlueCloud will be working with local African based organizations who will now be empowered to use BlueCloud’s delivery, distribution and implementation (DDI) strategies and technology mechanisms to deliver, distribute and properly implement initiatives to help organizations establish sustainable business models and regulatory processes in African nations.
BlueCloud’s globally proven business model known as Connector Service Provider (CSP) and its DDI mechanisms offers an innovative solution for industry stakeholders. Operating within the model, providers are directly connected to consumers for business and compliance purposes. Participating organizations can now distribute their products, services and specialties to consumer institutions to streamline the local healthcare and clinical research ecosystem. Global sponsors and CROs, governments and regulatory agencies can ensure transparency, site quality assurance, and identification of competent clinical trial operations locally. By providing real time connectivity between sites and sponsors, CROs and other stakeholders, local hospitals and sites can improve local sustainability by building study pipelines, while enabling sponsors to quickly identify competent sites based on geographical location and other inclusion/exclusion criteria while improving the process of developing products.
“By organizing African industry stakeholders into connected networks, BlueCloud Africa can pave the way to greater efficiencies as a member of the global healthcare and clinical research ecosystem - essential for improving the healthcare and clinical research industry so no patient is left behind’ – Stated Al O. Pacino, President BlueCloud by HealthCarePoint.
The BlueCloud Africa (DDI) strategy includes but is not limited to: 1) Delivery of smart city-based technology infrastructure to qualified healthcare and clinical research organizations. 2) Distribution of industry accepted guidelines, best practices and standards of care to providers and investigative sites to help streamline clinical trials regulatory process. 3) Distribution of basic healthcare and clinical research courses to local organizations to improve human subject protection and patient safety. 4) Distribute knowledge of patient populations based on limited data sets by using the BlueCloud Patient Mapping application. 5) Implement proper mechanisms that maintain “real-time” Professional Experience and Training Records 24/7 from opt-in connections to pre-qualify sites. 6) Implement proper mechanisms to improve transparency between qualified healthcare professionals, investigator sites, healthcare and clinical research sponsors and international institutions. 7) Provide DDI support infrastructure to maximize grants, university and government initiatives.
"We are leveraging BlueCloud’s DDI innovations to help Africa modernize its local health systems for the benefit of sponsor/CRO’s hospitals, sites, investigators, common and rare disease patient networks among other local industry stakeholders. BlueCloud ensures continual site optimization and transparency that is essential to the clinical research verification processes in the eyes of regulators.” - Stated Yonnie Otieno, Manager BlueCloud Africa.
“BlueCloud’s mission has always been to leave no patient behind by using implementation of guidelines, best practices and globally accepted standards. This process has been proven to eliminate waste, fraud and abuse in order to improve human subject protection and patient safety.” President of BlueCloud, Al O. Pacino explains, after 16 years in development, BlueCloud has evolved into a globally accepted DDI innovation desperately needed by organizations to promote and ultimately create smart cities with a sustainable infrastructure, helping create long-term sustainability for underdeveloped and developed countries alike.”
About BlueCloud by HealthCarePoint
A global innovation providing delivery, distribution and implementation (DDI) mechanisms for all industry stakeholders. The BlueCloud® is a Connector Service Provider (CSP ®). Nominated as one of the top innovations in the industry, BlueCloud® is the first independent (real-time / single sign-on) Professional Network for Healthcare and Clinical Research. A global collaborative network and essential catalyst of the ACRES global system, connecting all stakeholders in a secure, regulated, private system with a common adjudication process ensuring the identity of healthcare professionals to protect and ensure the safety of data exchange. Available in 167 countries and used by over 1.5 million healthcare professionals from Sponsors, CROs, research sites, hospitals, universities, and thousands of healthcare and clinical research stakeholders to connect, organize, centralize and share verifiable information in real-time for managerial and compliance activities. Saving the industry millions of dollars by eliminating redundancies, expediting study start up to ensure quality, transparency and compliance thus modernizing the industry using connectivity – creating a system that leaves no patient behind no matter what religion, race or social status. Reported by PRWeb 2 hours ago.
AUSTIN, Texas (PRWEB) November 13, 2018
BlueCloud by HealthCarePoint (HCP), a Texas-based healthcare and clinical research networking technology company founded by patient survivors, established BlueCloud Africa to work with local organizations to improve the healthcare and clinical research ecosystem using smart city development approaches. A “smart city” is commonly known as, “an area where information and communication technology, and various physical devices are connected to networks to optimize the efficiency of city operations and services and connect to citizens.” BlueCloud will be working with local African based organizations who will now be empowered to use BlueCloud’s delivery, distribution and implementation (DDI) strategies and technology mechanisms to deliver, distribute and properly implement initiatives to help organizations establish sustainable business models and regulatory processes in African nations.
BlueCloud’s globally proven business model known as Connector Service Provider (CSP) and its DDI mechanisms offers an innovative solution for industry stakeholders. Operating within the model, providers are directly connected to consumers for business and compliance purposes. Participating organizations can now distribute their products, services and specialties to consumer institutions to streamline the local healthcare and clinical research ecosystem. Global sponsors and CROs, governments and regulatory agencies can ensure transparency, site quality assurance, and identification of competent clinical trial operations locally. By providing real time connectivity between sites and sponsors, CROs and other stakeholders, local hospitals and sites can improve local sustainability by building study pipelines, while enabling sponsors to quickly identify competent sites based on geographical location and other inclusion/exclusion criteria while improving the process of developing products.
“By organizing African industry stakeholders into connected networks, BlueCloud Africa can pave the way to greater efficiencies as a member of the global healthcare and clinical research ecosystem - essential for improving the healthcare and clinical research industry so no patient is left behind’ – Stated Al O. Pacino, President BlueCloud by HealthCarePoint.
The BlueCloud Africa (DDI) strategy includes but is not limited to: 1) Delivery of smart city-based technology infrastructure to qualified healthcare and clinical research organizations. 2) Distribution of industry accepted guidelines, best practices and standards of care to providers and investigative sites to help streamline clinical trials regulatory process. 3) Distribution of basic healthcare and clinical research courses to local organizations to improve human subject protection and patient safety. 4) Distribute knowledge of patient populations based on limited data sets by using the BlueCloud Patient Mapping application. 5) Implement proper mechanisms that maintain “real-time” Professional Experience and Training Records 24/7 from opt-in connections to pre-qualify sites. 6) Implement proper mechanisms to improve transparency between qualified healthcare professionals, investigator sites, healthcare and clinical research sponsors and international institutions. 7) Provide DDI support infrastructure to maximize grants, university and government initiatives.
"We are leveraging BlueCloud’s DDI innovations to help Africa modernize its local health systems for the benefit of sponsor/CRO’s hospitals, sites, investigators, common and rare disease patient networks among other local industry stakeholders. BlueCloud ensures continual site optimization and transparency that is essential to the clinical research verification processes in the eyes of regulators.” - Stated Yonnie Otieno, Manager BlueCloud Africa.
“BlueCloud’s mission has always been to leave no patient behind by using implementation of guidelines, best practices and globally accepted standards. This process has been proven to eliminate waste, fraud and abuse in order to improve human subject protection and patient safety.” President of BlueCloud, Al O. Pacino explains, after 16 years in development, BlueCloud has evolved into a globally accepted DDI innovation desperately needed by organizations to promote and ultimately create smart cities with a sustainable infrastructure, helping create long-term sustainability for underdeveloped and developed countries alike.”
About BlueCloud by HealthCarePoint
A global innovation providing delivery, distribution and implementation (DDI) mechanisms for all industry stakeholders. The BlueCloud® is a Connector Service Provider (CSP ®). Nominated as one of the top innovations in the industry, BlueCloud® is the first independent (real-time / single sign-on) Professional Network for Healthcare and Clinical Research. A global collaborative network and essential catalyst of the ACRES global system, connecting all stakeholders in a secure, regulated, private system with a common adjudication process ensuring the identity of healthcare professionals to protect and ensure the safety of data exchange. Available in 167 countries and used by over 1.5 million healthcare professionals from Sponsors, CROs, research sites, hospitals, universities, and thousands of healthcare and clinical research stakeholders to connect, organize, centralize and share verifiable information in real-time for managerial and compliance activities. Saving the industry millions of dollars by eliminating redundancies, expediting study start up to ensure quality, transparency and compliance thus modernizing the industry using connectivity – creating a system that leaves no patient behind no matter what religion, race or social status. Reported by PRWeb 2 hours ago.
↧
CEA acquires BullSequana supercomputer from Atos equipped with Marvell ThunderX2 Arm-based processors
*Paris, Bruyères-le-Châtel, November 8 2018 - Atos, a global leader in digital transformation, announces it will provide its **BullSequana X1310, Atos' first Arm^®-based supercomputer, to **the CEA (French Alternative Energies and Atomic Energy Commission)'s Military Applications Division (CEA/DAM). **The machine will include the new Marvell^® ThunderX2^® 64-bit processors.*
CEA has been developing large, multi-physics, mission critical codes for over 40 years. This is particularly the case of CEA's Military Applications Division (CEA/DAM) since the end of the French nuclear tests 22 years ago. The validation of those codes is an important part of the work of developers and CEA's teams have observed that running these codes on different platforms from different architectures and using a variety of compilers and libraries from different sources helps find bugs and deviations from standards. Therefore, in order to provide the best validation environment at scale to its code developers, CEA/DAM ordered an Arm-based BullSequana cluster from Atos, using the new ThunderX2 CPU from Marvell.
Developed by Atos, this system is part of the Mont-Blanc 3 project, funded by the European Commission, which aims to assess the potential of Arm-based clusters to address exascale HPC needs, develop the corresponding software ecosystem and issue recommendations for an exascale ARM-based system.
The new model, which will be delivered at the end of 2018 in the Île-de-France CEA/DAM center, located at Bruyères-le-Châtel, includes a BullSequana rack with 92 BullSequana X1310 blades, three compute nodes per blade, dual Marvell ThunderX2 processors of 32 cores @ 2.2 GHz, based on the Armv8-A instruction set, with 256 GB per node and Infiniband^® EDR interconnect. The new ThunderX2 processor supports up to four threads per core with 8 memory channels delivering the combination of compute and memory bandwidth required for critical scientific workloads. The ThunderX2 family is fully compliant with Armv8-A architecture specifications as well as the Arm Server Base System Architecture (SBSA) and Arm Server Base Boot Requirements (SBBR) standards. ThunderX2 further accelerates adoption for Arm servers in the most demanding HPC deployments by providing the next level of computing performance and ecosystem readiness for commercial deployments.
In preparation for this installation, CEA/DAM has already received an initial set of blades to begin work on software porting, characterization and optimization. The first results show that this new cluster is a very promising architecture for memory intensive applications.
"We are proud to install the first BullSequana X1310 system at the CEA. This is the culmination of our long-term commitment to the Mont-Blanc European project, which assesses the potential of using Arm-based clusters to address exascale needs. This system is the commercial version of the prototype developed and built, by Atos, as part of the Mont-Blanc project for tests and evaluation. The availability of this new model is fully in-line with our policy of technological openness and our support for the European exascale supercomputer effort," said *Sophie Proust Houssiaux, Head of Big Data and Security Research and Development at Atos.*
"Marvell is pleased to partner with CEA and Atos to accelerate the overall development and optimization of key mission critical codes on the Arm architecture with ThunderX2. CEA is respected world-wide for its leadership in scientific innovation and high performance computing expertise and this collaboration will further enhance the maturity of the HPC software application ecosystem on ThunderX2," said *Gopal Hegde, Vice President and General Manager, Server Processor Business Unit at Marvell Semiconductor, Inc.*
*Atos at SC'18*
Atos will be at SC'18, the High Performance Annual Conference that takes place in Dallas, Texas, from 11-16 November, and will exhibit the full breadth of its High Performance Computing offer on booth #2213.
###
*About Atos*
Atos is a global leader in digital transformation with 120,000 employees in 73 countries and annual revenue of € 13 billion. European number one in Cloud, Cybersecurity and High-Performance Computing, the Group provides end-to-end Orchestrated Hybrid Cloud, Big Data, Business Applications and Digital Workplace solutions through its Digital Transformation Factory, as well as transactional services through Worldline, the European leader in the payment industry. With its cutting-edge technologies and industry knowledge, Atos supports the digital transformation of its clients across all business sectors. The Group is the Worldwide Information Technology Partner for the Olympic & Paralympic Games and operates under the brands Atos, Atos Syntel, Unify and Worldline. Atos is listed on the CAC40 Paris stock index.
For more details: www.atos.net
*Press contact*: Laura Fau | laura.fau@atos.net | +33 6 73 64 04 18 | @laurajanefau
*About the CEA and the Military Applications Division*
The French Alternative Energies and Atomic Energy Commission (CEA) is a public research organization working in four main areas: defense and security, low carbon energies (nuclear and renewables), technological research for industry and fundamental research. Building on its recognized expertise, the CEA takes part in implementing cooperation projects with a wide range of academic and industrial partners. With its 16,000 researchers and employees, it is a major player in European research and is expanding its international presence. In 2017, Thomson-Reuters / Clarivate identified the CEA as the most innovative public research organization in Europe.
More information: www.cea.fr
The CEA's Military Applications Division ("DAM") takes charge of defense and security missions. The DAM is responsible for the design, manufacture, through-life support and dismantling of the nuclear warheads that equip France's sea- and airborne deterrence forces. It is also responsible for the design and manufacture of the nuclear reactors and reactor cores on the French Navy submarines and aircraft carrier. It assists the Navy with in-service follow-up and through-life support for these reactors. The DAM is in charge of procuring strategic nuclear materials required for the nation's deterrence. The DAM also contributes to national and global security through the technical support it provides to the authorities relative to the prevention of nuclear proliferation and terrorism.
More information: www-dam.cea.fr
*Press contact*: Nicolas Tilly - +33 1 64 50 17 16 - nicolas.tilly@cea.fr
*About Marvell*
Marvell first revolutionized the digital storage industry by moving information at speeds never thought possible. Today, that same breakthrough innovation remains at the heart of the company's storage, processing, networking, security and connectivity solutions. With leading intellectual property and deep system-level knowledge, Marvell's semiconductor solutions continue to transform the enterprise, cloud, automotive, industrial, and consumer markets. To learn more, visit: https://www.marvell.com/
Press contact: Kristin Hehir - +1 408-222-8744 - kristinh@marvell.com
*Attachment*
· Click here for PDF.pdf Reported by GlobeNewswire 2 hours ago.
CEA has been developing large, multi-physics, mission critical codes for over 40 years. This is particularly the case of CEA's Military Applications Division (CEA/DAM) since the end of the French nuclear tests 22 years ago. The validation of those codes is an important part of the work of developers and CEA's teams have observed that running these codes on different platforms from different architectures and using a variety of compilers and libraries from different sources helps find bugs and deviations from standards. Therefore, in order to provide the best validation environment at scale to its code developers, CEA/DAM ordered an Arm-based BullSequana cluster from Atos, using the new ThunderX2 CPU from Marvell.
Developed by Atos, this system is part of the Mont-Blanc 3 project, funded by the European Commission, which aims to assess the potential of Arm-based clusters to address exascale HPC needs, develop the corresponding software ecosystem and issue recommendations for an exascale ARM-based system.
The new model, which will be delivered at the end of 2018 in the Île-de-France CEA/DAM center, located at Bruyères-le-Châtel, includes a BullSequana rack with 92 BullSequana X1310 blades, three compute nodes per blade, dual Marvell ThunderX2 processors of 32 cores @ 2.2 GHz, based on the Armv8-A instruction set, with 256 GB per node and Infiniband^® EDR interconnect. The new ThunderX2 processor supports up to four threads per core with 8 memory channels delivering the combination of compute and memory bandwidth required for critical scientific workloads. The ThunderX2 family is fully compliant with Armv8-A architecture specifications as well as the Arm Server Base System Architecture (SBSA) and Arm Server Base Boot Requirements (SBBR) standards. ThunderX2 further accelerates adoption for Arm servers in the most demanding HPC deployments by providing the next level of computing performance and ecosystem readiness for commercial deployments.
In preparation for this installation, CEA/DAM has already received an initial set of blades to begin work on software porting, characterization and optimization. The first results show that this new cluster is a very promising architecture for memory intensive applications.
"We are proud to install the first BullSequana X1310 system at the CEA. This is the culmination of our long-term commitment to the Mont-Blanc European project, which assesses the potential of using Arm-based clusters to address exascale needs. This system is the commercial version of the prototype developed and built, by Atos, as part of the Mont-Blanc project for tests and evaluation. The availability of this new model is fully in-line with our policy of technological openness and our support for the European exascale supercomputer effort," said *Sophie Proust Houssiaux, Head of Big Data and Security Research and Development at Atos.*
"Marvell is pleased to partner with CEA and Atos to accelerate the overall development and optimization of key mission critical codes on the Arm architecture with ThunderX2. CEA is respected world-wide for its leadership in scientific innovation and high performance computing expertise and this collaboration will further enhance the maturity of the HPC software application ecosystem on ThunderX2," said *Gopal Hegde, Vice President and General Manager, Server Processor Business Unit at Marvell Semiconductor, Inc.*
*Atos at SC'18*
Atos will be at SC'18, the High Performance Annual Conference that takes place in Dallas, Texas, from 11-16 November, and will exhibit the full breadth of its High Performance Computing offer on booth #2213.
###
*About Atos*
Atos is a global leader in digital transformation with 120,000 employees in 73 countries and annual revenue of € 13 billion. European number one in Cloud, Cybersecurity and High-Performance Computing, the Group provides end-to-end Orchestrated Hybrid Cloud, Big Data, Business Applications and Digital Workplace solutions through its Digital Transformation Factory, as well as transactional services through Worldline, the European leader in the payment industry. With its cutting-edge technologies and industry knowledge, Atos supports the digital transformation of its clients across all business sectors. The Group is the Worldwide Information Technology Partner for the Olympic & Paralympic Games and operates under the brands Atos, Atos Syntel, Unify and Worldline. Atos is listed on the CAC40 Paris stock index.
For more details: www.atos.net
*Press contact*: Laura Fau | laura.fau@atos.net | +33 6 73 64 04 18 | @laurajanefau
*About the CEA and the Military Applications Division*
The French Alternative Energies and Atomic Energy Commission (CEA) is a public research organization working in four main areas: defense and security, low carbon energies (nuclear and renewables), technological research for industry and fundamental research. Building on its recognized expertise, the CEA takes part in implementing cooperation projects with a wide range of academic and industrial partners. With its 16,000 researchers and employees, it is a major player in European research and is expanding its international presence. In 2017, Thomson-Reuters / Clarivate identified the CEA as the most innovative public research organization in Europe.
More information: www.cea.fr
The CEA's Military Applications Division ("DAM") takes charge of defense and security missions. The DAM is responsible for the design, manufacture, through-life support and dismantling of the nuclear warheads that equip France's sea- and airborne deterrence forces. It is also responsible for the design and manufacture of the nuclear reactors and reactor cores on the French Navy submarines and aircraft carrier. It assists the Navy with in-service follow-up and through-life support for these reactors. The DAM is in charge of procuring strategic nuclear materials required for the nation's deterrence. The DAM also contributes to national and global security through the technical support it provides to the authorities relative to the prevention of nuclear proliferation and terrorism.
More information: www-dam.cea.fr
*Press contact*: Nicolas Tilly - +33 1 64 50 17 16 - nicolas.tilly@cea.fr
*About Marvell*
Marvell first revolutionized the digital storage industry by moving information at speeds never thought possible. Today, that same breakthrough innovation remains at the heart of the company's storage, processing, networking, security and connectivity solutions. With leading intellectual property and deep system-level knowledge, Marvell's semiconductor solutions continue to transform the enterprise, cloud, automotive, industrial, and consumer markets. To learn more, visit: https://www.marvell.com/
Press contact: Kristin Hehir - +1 408-222-8744 - kristinh@marvell.com
*Attachment*
· Click here for PDF.pdf Reported by GlobeNewswire 2 hours ago.
↧
More Pages to Explore .....
